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Advisor: Stephen G. DiMagno 
 Diaryliodonium salts have been studied continuously since the first report of their 
synthesis in 1894. Diaryliodonium salts are I(III) derivatives that are air- and moisture-
stable. The reactivity of these compounds resembles the organometallic chemistry of 
heavy transition metal ions such as Pb(IV), Hg(II), Th(III), and Pd(II). A significant 
advantage of diaryliodonium salts is that they can carry undergo many of the aryl 
functionalization reactions of heavy metal organometallic complexes, yet they have little 
to no toxicity and they are relatively inexpensive to prepare. The DiMagno laboratory 
uses diaryliodonium salts as precursors in the final synthetic step of 
radiopharmaceuticals; given that radiotracer prepared in this manner need to be injected 
into humans shortly after their synthesis, it is a virtual requirement that precursors and 
labeling reactions do not generate potentially toxic byproducts in radiotracer 
preparations.  
 This thesis comprises to two distinct projects. The first is the discussion of the 
synthesis of the highly electron-rich diaryliodonium salts in which one of the rings is an 
indole. Diaryliodonium salts featuring indole substituents constitute a relatively 
uncommon and poorly characterized class of compounds to date. The chapter will discuss 
the synthesis of diaryliodonium salts that feature 2- and 5-indole substituents, and will 
report nucleophilic substitution of these compounds with a variety of nucleophiles. 
  
Progress towards synthesizing diaryliodonium salts that could serve as precursors to 
radiofluorinated or radioiodinated serotonin, tryptamine, and tryptophan derivatives, 
along with model studies that provide insight into the nature of nucleophilic substitution 
for these substrates, will be reported. Because of the electron-rich nature of the C-2 
position of indole, conventional methods to synthesize diaryliodonium salts featuring this 
moiety failed. Here I discuss application of a novel synthetic approach to diaryliodonium 
salts, developed by Dr. Bao Hu in our group, which features condensation of Grignard 
reagents with aryl iodonium precursors. This reaction proved to be an extremely useful 
tool for the synthesis of extremely electron rich diaryliodonium salts that we were unable 
to prepare using the oxidative coupling methodology developed in our laboratory.   
 The second part of this thesis will discuss the synthesis of diaryliodonium salts on 
solid-phase resins, and the potential for using solid phase techniques for  
radiopharmaceutical synthesis Very little previous work has been done in synthesizing 
diaryliodonium salts on a solid support, so this work is quite new, and not fully 
developed at this time.  
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CHAPTER 1 
SYNTHESIS OF INDOLE-BASED DIARYLIODONIUM SALTS 
1.1.1 Introduction of Diaryliodonium Salts and Indoles 
Iodine is the largest and most electropositive of the nonradioactive halogens. It is 
most commonly recognized in its I(I) oxidation state, however, it is also able to form 
multivalent compounds. Compounds containing hypervalent iodine have recently 
received increased attention in literature as alternatives to organometallic reagents.1 Of 
particular interest to this thesis is iodine (III), which has similar reactivity to metals such 
as lead(IV), mercury(II), thallium(III) and palladium(II).1 However, iodine(III) has lower 
toxicity (1100 μg for human adults)2 than lead (no safe level for human adults)3, mercury 
(10 μg/L)4, and thallium (3 μg/L).4 Iodine(III) is also relatively inexpensive ($0.08/g) 
compared to thallium ($0.48/g) and palladium ($58/g)5. 
Organic iodine(III) compounds are classified by the ligands attached to the iodine 
atom (Figure 1-1). Three types of organic iodine(III) compounds are used in this work. 
Iodosylarenes 3 and [bis(acyloxy)iodo]arenes 4 are strong oxidizing agents.6 The most 
commonly used iodine (III) oxidizing agent is (diacetoxyiodo)benzene (PhI(OAc)2). 
Aryliodonium salts 10 are used as arylation electrophiles and are also commonly used in 
lithography and as polymerization photoinitiators.7 When R=Ar, these compounds are 
called diaryliodonium salts, which are most commonly used as arylating agents.  
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The accepted conformation of diaryliodonium salts is a T-shape (Figure 1-2).6,8 
Diaryliodonium compounds place the most electronegative substituent on the axial 
position and the two aryl groups on the remaining positions.9 Exchange between the aryl 
groups are in rapid equilibrium, but it is dependent on solvent and the ion.10 The distance 
between iodine and the nearest anion is approximately 2.6-2.8 Å,8 giving the salt ionic 
character.  
  
 
Data in the patent literature from the 1970’s established the biocidal and 
antimicrobial activity of numerous diaryliodonium salts.11-18 These salts also have low 
toxicity to mammals (LD50 = 56 mg/kg for Ph2I-Cl in mice) and have potential as 
disinfectants and preservatives.6 The low toxicity over similarly reactive, toxic metals has 
led to a resurgence of diaryliodonium salts in the literature. They are mainly used as an 
Ar
IF F
Ar
ICl Cl Ar(IO)n
Ar
IO O
O O
1 2 3 4
N
I
X
Z O
I
X
Y YO
Ar
I RX-
Ar
I
R
R
Ar
I N
R
6 7 8 9 10
Ar
IHO OSO2R
5
Figure 1-1 Classes of iodine (III) compounds  
Figure 1-2 Structures of hypervalent iodine species 
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aryl transfer reagent. In the DiMagno lab, diaryliodonium salts are used for the 
functionalization of highly electron-rich arenes. 
When the diaryliodonium salt is heated, it undergoes thermolysis with 
nucleophiles through a Meisenheimer-like transition state (Scheme 1-1). Thermolysis of 
unsymmetrical diaryliodonium salts results in the nucleophile being directed towards the 
more electron-poor arene,19 which is better able to tolerate the build-up of negative 
charge in the transition state.20 Electron-rich arenes such as 4-methoxyphenyl21 and 
thienyl22 are commonly used as electron-rich directing groups. Thermolysis of 
diaryliodonium salts is a simple synthesis for the functionalization of electron-rich and 
electron-poor aromatic molecules at the ortho-, meta-, or para-positions. 
  
 
Diaryliodonium salts are used to functionalize arenes with a variety of 
nucleophiles including iodide,23,24 bromide,24,25 and fluoride.26 Of these, the DiMagno 
group has particular interest in incorporating [18F]-fluoride and [124I]-iodide for Positron 
Emission Tomography (PET) imaging agents.  
PET is a noninvasive molecular imaging technique that uses a radioactive tracer 
to study biological functions. Common radionuclides used in PET are carbon-11, 
fluorine-18, gallium-68, and iodine-124. Of these, fluorine-18 is one of the leading 
positron emitting radioisotopes because of its moderately short half-life (109.8 min.), and 
I
D
I
Nu
Ar
Nu
Ar
Nu + Ar-I
Scheme 1-1 General mechanism of diaryliodonium salt thermolysis 
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high specific activity and high energy positron.27 Diaryliodonium salts were first used to 
radiofluorinate tracers by Pike in 1995.28   
The most common synthetic strategy for diaryliodonium salts6 begins with an 
iodoarene oxidized by MCPBA29 or sodium periodate30 and a moderate acid such as 
acetic acid.31 This gives the oxidized iodosylarene (Ar-IX2), which can be isolated or 
carried forward in situ.6 The iodosylarene is introduced to an organometallic arene or a 
simple arene with a Brønsted acid such as tosylic acid29 or triflic acid30 and, in some 
cases, a metal catalyst31 (Scheme 1-2).  
 
 
 A major drawback of the traditional synthetic method is its incompatibility with 
acid sensitive functional groups. Many acid-labile protecting groups such as t-butyl 
carbamate (Boc) and ethoxymethyl ether cannot be used with acids such as tosylic acid 
(pKa=8.5 in acetonitrile) and triflic acid (pKa=0.7 in acetonitrile).32 These protecting 
groups are ideal for PET because of their simple and fast deprotection. To synthesize 
diaryliodonium salts with acid sensitive protecting groups, the DiMagno lab has 
developed a synthetic approach33 that avoids using Brønsted acids (Scheme 1-3). The 
iodoarene is oxidized using F-TEDA-BF4 (Selectfluor
TM) in the presence of TMSOAc. 
The iodosylarene is introduced to the organometallic trifluoroborate with TMSTFA. 
Boronate compounds have low toxicity34 and are air and moisture stable. TMSTFA and 
Scheme 1-2 General synthetic strategy for synthesis of diaryliodonium salts 
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TMSOAc are Lewis acids used in place of the strong Brønsted acids that are commonly 
used in diaryliodonium salt syntheses. Efficient functionalization of arenes via 
diaryliodonium salts requires an electron-rich directing group. In the DiMagno group, 4-
methoxyphenyl is used.33 The iodine (III) arene can be synthesized on the anisole 
directing group or the tracer (Scheme 1-3). 
 
 
Using the DiMagno lab methodology, I turned my attention to synthesizing a 
diaryliodonium salt of an indole. Indoles are bicyclic, heterocyclic molecules that are 
sparingly studied in literature as ligands in diaryliodonium salts or radiotracers for PET. 
Indoles are relevant in pharmaceuticals,35 agrochemicals,36 and organic electronics.37 
Indole is the core structure of a large number of pharmaceutically relevant compounds 
(Figure 1-3), including tryptamine, a neuromodulator; 5-hydroxytryptamine (serotonin), a 
regulator of mood, appetite and sleep; L-Tryptophan, an essential amino acid; melatonin, 
a hormone that anticipates the daily onset of darkness; indomethacin, an NSAID; and 
N,N-Dimethyltryptamine, a hallucinogen.35 I focused my attention on serotonin and L-
Tryptophan. 
Ar I
1.3 eq SelectfluorTM
2.6 eq TMSOAc
Ar I
OAc
OAc
TMSTFA
Ar I TFA
Ar-BF3K +
BF3K
O
O
I
O
OAcAcO
TMSTFA
Ar I TFA
O
Scheme 1-3 General DiMagno lab methodology for synthesis of diaryliodonium salts 
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 The electronic structure of indole, calculated by Pullman and Pullman,37 has a 
high negative charge on C-2 and a lesser negative charge on C-1. Carbons C4 through C7 
are much less electron-rich,38 so I believed that thermolysis of diaryliodonium salts at the 
C4, C5, C6, or C7 positions would result in fewer side products. Synthesis of 
diaryliodonium salts at the highly electron-rich C2-position on indoles will be discussed 
in greater detail later in this chapter.  
Thermolysis of diaryliodonium salts potentially produces four major products39 
(Scheme 1-4), but for radiosynthesis of tracers in PET, minimal side products are desired. 
Using an electron-rich directing group such as 4-methoxy phenyl limits these side 
products. However, with a highly electron rich arylating agents like indole, side products 
increase. 
N
H
NH2
N
H
NH2
Tryptamine
HO
Serotonin
N
H
OH
O
NH2
L-Tryptophan
Melatonin
N
H
N
H
O O
Indomethacin
N
O
OH
O
O
Cl
N
H
N
N,N-Dimethyltryptamine
Figure 1-3 Indoles of pharmaceutical relevance  
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1.1.2 Synthesis of tert-butyl 3-((4-methoxyphenyl)(((trifluoromethyl)sulfonyl)oxy)-λ3-
iodanyl)-1H-indole-1-carboxylate 
My first goal was to synthesize a radiotracer of serotonin. To quantify the side 
products, however, I needed to first synthesize a diaryliodonium salt at the C-5 position 
of indole. The C-F bond is similar in bond length and size to both C-H and C-OH groups 
(Table 1-1),40 so it can be substituted for the bonds with minimal steric perturbation. By 
substituting the C-OH bond of serotonin with a C-18F bond, we would be able to study 
the metabolism of serotonin via PET.  
 
 
 
 
 
To estimate the electronics of serotonin, I synthesized two test compounds to 
determine what the selectivity of a thermolysis reaction would be. There has only been 
one previous synthesis of a diaryliodonium salt at the C-5 position of indole, which was 
I
D
Nu
O
R
I
R
Nu
R
I
O
Nu
O
Bond Length [Å] van der Waals radius[Å] Total Size [Å] 
C-H 1.09 1.2 2.29 
C=O 1.23 1.5 2.73 
C-O- 1.43 1.52 2.95 
C-F 1.35 1.47 2.82 
O-H 0.96 1.2 2.16 
Scheme 1-4 Possible products of thermolysis 
Table 1-1 Steric consequences of fluorine 
  
19 
by Zhdankin41 in 1992 (Scheme 1-5). He synthesized a symmetrical indole triflate 
diaryliodonium salt via a tin intermediate in 10% yield.   
 
 
For the first test compound, I began with 5-iodoindole 12. I synthesized tert-
butyl-5-iodo-1H-indole-1-carboxylate 13,42 using a standard Boc protection. I 
synthesized the oxidized product 14 using 1.3 equivalents Selectfluor™ and 2.6 
equivalents TMSOAc. The oxidation produced more than 90% oxidized product, which I 
carried forward in situ without further purification. I coupled the oxidized indole with 
trifluoro(4-methoxyphenyl)-λ4-borane, potassium salt, and ion exchanged with sodium 
hexafluorophosphate to give the diaryliodonium salt 15 (Scheme 1-6). 
 
 
Synthesis from the oxidized iodo-indole forms the diaryliodonium salt using the 
(1-(tert-butoxycarbonyl)-1H-indol-5-yl)-λ3-iodanediyl diacetate as an electrophile and 
trifluoro(4-methoxyphenyl)-l4-borane, potassium salt as the nucleophile. However, the 
N
H
Sn
F S
F
F O
-
O
O
NC
I
CN
+
N
H
I
N
H
OSO2F3
N
I
Boc
N
H
I 1.5 eq (Boc)2O
0.5 eq DMAP
2.0 Et3N
0.1 M CH3CN
74%
1.3 eq Selectfluor
2.6 eq TMSOAc
0.1 M CH3CN
Used in situ
N
(AcO)2I
Boc
BF3K
O
1. 1.0 eq
1.0 eq TMSTFA
2. NaPF6
56%
N
I
Boc
F6P
O
12 13 14 15
Scheme 1-5 Zhdankin synthesis of bis indole iodonium salt 
Scheme 1-6 Synthesis of tert-butyl 5-((hexafluoro-λ7-phosphanyl)(4-methoxyphenyl)-
λ3-iodanyl)-1H-indole-1-carboxylate from 5-iodoindole 
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diaryliodonium salt can also be synthesized from the oxidized anisole and the indole 
boronate. The boronate compound can easily be synthesized from 5-bromoindole by 
palladium cross-coupling.43  Bromo-indoles are significantly cheaper ($130.50 for 25 g)44 
than iodo-indoles ($365.00/25 g).45 Therefore, if the synthesis of tert-butyl 5-
((hexafluoro-λ7-phosphanyl)(4-methoxyphenyl)-λ3-iodanyl)-1H-indole-1-carboxylate 
from 5-bromoindole was successful, it would indicate that I could synthesize all serotonin 
and tryptophan diaryliodonium salts from the cheaper bromo precursors. To synthesize 
17, I Boc-protected 5-bromoindole46 (Scheme 1-7) using common Boc protection 
methodology. I synthesized the boronic ester 18 using palladium catalysis with 
bis(pinacolato)diboron. The boronic ester was converted to the trifluoroborate 19 with 
potassium bifluoride. I coupled the trifluoroborate with (4-methoxyphenyl)-λ3-iodanediyl 
diacetate and TMSTFA. As was hoped, synthesis of the salt proceeded easily without 
issue, thus opening up a cheaper way to make these compounds(?).  
 
 
1.5 eq (Boc)2O
0.5 eq DMAP
2.0 Et3N
0.1 M CH3CN
88%
N
H
Br
N
Br
Boc
2 eq (bis)pinacolatodiboron
5 mol% dppf
5 mol % PdCl2
10 eq KOAc
0.1 M CH3CN
80 C overnight
Used in situ
N
B
Boc
O
O
6 eq KHF2
EtOH/H2O
55%
N
KF3B
Boc
1. 1 eq
I
AcO OAc
O
TMSTFA
CH3CN
2. NaPF6, MeOH/H2O
66%
N
Boc
I
F6P
O
17 18 19
15
16
Scheme 1-7 Synthesis of tert-butyl 5-((hexafluoro-λ7-phosphanyl)(4-methoxyphenyl)-
λ3-iodanyl)-1H-indole-1-carboxylate from 5-bromoindole 
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Thermolysis of tert-butyl 5-((hexafluoro-λ7-phosphanyl)(4-methoxyphenyl)-λ3-
iodanyl)-1H-indole-1-carboxylate, 15, with tetra-butylammonium azide showed an 
incomplete selection for functionalization of the indole (Figure 1-4). The incomplete 
functionalization is shown by the presence of 1-azido-4-methoxybenzene in the crude 
NMR. The lower than expected selectivity suggests the C-5 position of indole ligand on a 
diaryliodonium salt with an anisole-directing group could be too electron-rich for PET 
radiosynthesis via diaryliodonium salts. To improve the selectivity of the thermolysis, a 
more electron-withdrawing protecting group such as tosyl or a more electron-rich 
directing group such as cyclophane47 could be used. Cyclophane directs nucleophiles in 
thermolysis by regiochemical control. The out-of-plane steric bulk destabilizes the 
transition state, and permits regiospecific thermolysis47. The fault of diaryliodonium salts 
with a cyclophane ligand is the complexity of their synthesis. The synthesis requires 
formation of the cyclophane Zn complex. 
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1.1.3 Synthesis of tert-butyl 5-(2-((tert-butoxycarbonyl)amino)ethyl)-3-((4-
methoxyphenyl)(((trifluoromethyl)sulfonyl)oxy)-λ3-iodanyl)-1H-indole-1-
carboxylate 
[18F]-5-fluoro-tryptamine could serve as a radiotracer for either serotonin or 
tryptamine metabolism depending on its binding capacity. Minimal studies have been 
done on the binding capacity of 5-fluorotryptamine. James published in 198248 that 5-
fluorotryptamine binds to normal and denatured DNA, but no in vivo studies have been 
completed to date. Serotonin is well known to be a target of many 
psychopharmaceuticals.49-51 Tryptamine is biologically generated by decarboxylation of 
L-tryptophan by L-amino acid decarboxylase.52 Tryptamine is also of pharmaceutical 
relevance in the psychopharmaceutical field. Tryptamine is highly metabolized by 
depressed patients;53 however, it normalizes with treatment, while tryptophan and 
serotonin metabolism remain constant throughout.54 An increase in tryptamine 
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2Figure 1-4 Thermolysis of tert-butyl 5-((hexafluoro-λ7-phosphanyl)(4-
methoxyphenyl)-λ3-iodanyl)-1H-indole-1-carboxylate with TBAN3 in CD3CN 
  
23 
metabolism is also shown in schizophrenics.55 All studies showing abnormal tryptamine 
metabolism in psychiatric disorders have been by urinary analyses, and new studies have 
not been done using other technology. The goal of synthesizing [18F]-5-fluorotryptamine 
would be to study the metabolism of tryptamine and serotonin in a healthy and depressed 
model. The results could lead to new revelations about tryptamine’s role in depression 
and other psychiatric disorders. If there are different PET results between a depressed and 
normal model, the results could also validate PET as a diagnostic tool for depression. 
To synthesize tert-butyl 3-(2-((tert-butoxycarbonyl)amino)ethyl)-5-((hexafluoro-
l7-phosphanyl)(4-methoxyphenyl)-λ3-iodanyl)-1H-indole-1-carboxylate 26, I began with 
a modified synthesis of 5-bromotryptamine56 (Scheme 1-8). With the modified synthesis, 
I had a fully protected 5-bromotryptamine, which could be converted to the 
trifluoroboronate and coupled (4-methoxyphenyl)-l3-iodanediyl diacetate to give the 
diaryliodonium salt. 
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It is known that the 2-position of indole is the most electron-rich position.37 
Because of the high electron density, formylation via a Villsmeier-Haack reaction of 16 
proceeded in a quantitative fashion at room temperature to give 19. Using a Henry 
reaction, I synthesized the nitro alkene 20 nearly quantitatively. I reduced with lithium 
aluminum hydride to give the amine 21. Schotten-Baumann Boc protection gave the 
mono-protected tryptamine 22. I then proceeded with Boc-protecting the remaining 
amines 23. Using the same methodology for synthesis of diaryliodonium salts that I had 
used for the indole, I synthesized the boronic ester using palladium-catalyzed cross 
coupling. The boronic ester 24 was found to be unstable, and I carried it forward without 
purification. I synthesized the fluoro-boronate 25 with potassium bifluoride, and coupled 
25 with (4-methoxyphenyl)-λ3-iodanediyl diacetate to give the salt 26.  
Previous work in the DiMagno lab by Dr. Linlin Qin57 had shown that thermolysis 
to the functionalized azide proceeded fastest, at the lowest temperature, and with the best 
selectivity. Because the test indole compounds proceeded with imperfect selection, I tried 
the thermolysis of tert-butyl 3-(2-((tert-butoxycarbonyl)amino)ethyl)-5-((hexafluoro- λ 7-
phosphanyl)(4-methoxyphenyl)-λ3-iodanyl)-1H-indole-1-carboxylate with azide to 
estimate the selectivity. However, selectivity proceeded with a 2:1 functionalization of 
the indole 28 to the iodinated indole 29.  The incomplete selectivity is most obvious 
looking at the anisole peaks, where iodo-anisole is in 2:1 ratio with the functionalized 
anisole (Figure 1-5).  
Scheme 1-8 Synthesis of tert-butyl 3-(2-((tert-butoxycarbonyl)amino)ethyl)-5-
((hexafluoro-l7-phosphanyl)(4-methoxyphenyl)-λ3-iodanyl)-1H-indole-1-carboxylate 
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Because of the incomplete selectivity, continuing forward with the indole project 
was impractical without a more electron-withdrawing protecting group or a better 
directing group. Different protecting group options, such as acetate, tosyl, and triflate, are 
available to withdraw electron density from the aromatic ring. However, most other 
protecting groups are not plausible for use with radiofluorination, as all require long and 
harsh deprotection strategies.59 
1.1.4 Radiofluorination of Tryptophan and Future Studies 
The final goal of the indole project was to synthesize a radiofluorinated 
tryptophan. Tryptophan is an essential amino acid, and it is of interest in PET imaging 
because of its increased metabolism in tumor cells.59-61 It is known that Large Amino 
Acid Transporter 1 (LAT1) transports large neutral amino acids such as tyrosine, 
Figure 1-5 Crude thermolysis of Tryptamine with TBAN3 in CD3CN 
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tryptophan, and phenylalanine, with high affinity (15-50microM).62 LAT1 also transports 
chemotherapy drugs that mimic amino acids like melphalan.63, 64 I wanted to synthesis 
[18F]-Fluoro-L-Tryptophan because it has potential to be used alongside [18F]-2-F-
fluorodeoxyglucose ([18F]-FDG) in PET. 
[18F]-FDG is the number one radiotracer used in PET imaging studies65. 
Currently, over 90% of PET scans use [18F]-FDG for imaging the metastasis of cancer. 
However, [18F]- FDG is also used for the assessment of glucose metabolism in the 
heart,66 brain,67 and lungs.68 Tumors in these major organs are unable to be scanned with 
[18F]-FDG because of the organ’s high glucose uptake. The large uptake by the heart, 
brain, and lungs leads to a large amount of background noise, which hides any tumors. 
There is a need for general PET imaging tools that can scan tumors in glucose high-
uptake organs. LAT1 is increased in tumor cells because of their high amino acid 
metabolism.69 Tryptophan metabolism is increased in meningiomas,70 breast cancer,71 and 
neuroepithelial tumors.72 Because of the increased metabolism of tryptophan in tumor 
cells, I believe that a [18F]-fluoro-L-tryptophan could be a useful tracer for PET imaging. 
Given the incomplete selectivity of the indole and tryptamine thermolyses, the 
synthesis of a diaryliodonium salt tryptophan needs to be different than the test 
compounds. More electron-withdrawing groups such as acetyl or tosyl would need to be 
used. The problem is that electron-withdrawing groups require harsh, long deprotection. 
Acetyl is a strong, base-labile protecting group that would likely require overnight 
refluxing in strong base to completely remove.73 Tosyl would require a more difficult 
deprotection with a reducing group like Na/NH3 or Zn/HCl.
73 In PET, time is of the 
essence. Deprotection occurs after the introduction of the radionuclide. The longer the 
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deprotection, the less radioactivity is maintained for introduction into the patient. A better 
directing group such as cyclophane47 could be used.  
My proposed synthesis (Scheme 1-9) includes flexibility of the protecting group 
on the indole ring.74-75 I synthesized all precursors up to 38, which requires a new 
protection strategy. I begin with L-Glutamic Acid 29, an amino acid that is both cheap 
and accessible. Ester protection with thionyl chloride gave the diester 30 quantitatively. I 
protected the first free amine with Schotten-Baumann Boc protection 31, and a standard 
Boc protection would gave the desired 32. Reduction of the single ester with DIBAL 
would give the aldehyde 33.74 Next, the aldehyde would be coupled with a 2-iodo-
nitroaniline 34-3776-79 to give nitrotryptophan 38. I successfully synthesized methyl (S)-2-
((tert-butoxycarbonyl)amino)-3-(6-nitro-1H-indol-3-yl)propanoate with this strategy. 
Because the aniline can be used with the nitro group at any position, the iodonium salt 
could be synthesized at the C4, C5, C6, or C7 position of tryptophan.80 The unprotected 
nitrogen of the indole would need to be protected with an electron-withdrawing 
protecting group to avoid the incomplete thermolysis seen in the indole test compounds. 
Reduction of the nitro group to the amine would be done with Zn and 5% HCl to avoid 
deprotection of the Boc group 40.75 The diazo compound would be formed and converted 
to the iodide 41. To synthesize the final desired salt 42, I would oxidize the iodo-
tryptophan with Selectfluor and TMSOAc, and couple it with (4-methoxyphenyl)-λ3-
iodanediyl diacetate. 
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Scheme 1-10 Synthesis of 2-iodonitroaniline Precursors 
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Scheme 1-9 Proposed Synthesis of Iodonium Tryptophan 
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1.2.1 Introduction to the Synthesis of Indole Iodonium Salts via Novel Grignard 
Reagent 
Quaternary α-alkyl α-aryl amino acids are of biological interest because of their 
increased stability81 and use as inhibitors for enzymes not usually inhibited by simple 
amino acids.82  
The formation of C-C bonds via diaryliodonium salts is sparsely studied,83 and 
thus presents a synthetic challenge. My lab mate Jayson Kempinger developed a general 
synthetic strategy (Scheme 1-11) that could be used to synthesize a vast number of 
functionalized quaternary aromatic amino acids via diaryliodonium salts. Synthesis 
begins with either ethyl 2-bromopropanoate or ethyl 2-bromobutanoate 44, which are 
reacted with sodium nitrite to give 45.84 Reaction with sodium metal gives the carbanion 
46. When the carbanion is added to a diaryliodonium salt 47 with 25 mol% phase transfer 
catalyst TBACl, the carbanion replaces the triflate anion. Thermolysis of the exchanged 
salt gives the desired quaternary amino acid 49 and the iodinated product 50. His work 
included functionalized phenylalanine and tyrosine. Of particular interest to me, because 
of my work with indoles, was a quaternary tryptophan. 
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Multiple quaternary α-alkyl α-aryl tryptophans have been synthesized for 
biological purposes. The tryptophan analogues are reverse transcriptase inhibitors85 and 
Beta amyloid self-assembly inhibitors.86 among many others. However, many are 
synthesized under harsh conditions with heavy metals85 or strong acids.86 Simple, 
protecting group stable synthetic conditions could make the tryptophan analogue 
compounds more available and useful. 
Kempinger’s work focused on using symmetrical salts for the synthesis, so I 
began with a synthetic design for a bis-diaryliodonium indole salt at the C-2 position. The 
C-2 position has been significantly more studied than the C-4 through C-7 positions, 
however, there have been no symmetrical salts of indole at the C-2 position synthesized. 
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Scheme 1-11 General Synthetic Strategy for synthesis of quaternary amino acids via 
diaryliodonium salts 
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The high electron-density at the C-2 position makes it challenging as it is very common 
for one-electron reduction and polymerization to occur.87 
Synthesis of the symmetrical salt requires an oxidized I(III) indole, so I began 
with the oxidation of the 2-iodo protected indole (Scheme 1-12). I synthesized 2-
iodoindole from indole using potassium hydroxide and iodine in DMF to give 52. The 
reaction, as previously reported,88 proceeded quantitatively. I then protected the amine 
with a Boc group to give 53.89 When I attempted to oxidize the iodo-indole, however, the 
reaction produced a myriad of soluble and insoluble side products, most likely from the 
known polymerization that occurs at the C-2 position of indole87. There are no published 
syntheses of an oxidized 2-Iodoindole, and other common synthetic strategies require 
strong acids, which would deprotect the Boc. The protecting group incompatibility 
hindered further progress on the synthesis, and a bis salt became unobtainable.  
 
 
1.2.2 Use of Transmetalation for Diaryliodonium Salt Synthesis 
Synthesis of diaryliodonium salts proceeds with a general strategy of an oxidized 
iodo-compound coupled to a metal6. Different metals used are tin(IV),90 boron,33 and 
zinc.47 The metal can be synthesized on either the substrate or the directing group, which 
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Scheme 1-12 Attempted synthesis of oxidized 3-iodoindole 
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allows for flexibility in synthesis. The metal and oxidized iodoarene are coupled using a 
strong acid.  
The syntheses of diaryliodonium salts at the C-2 position of indole have been 
reported using acids such as tosylic acid91 and acetic acid.92 Using tosylic acid, Suna92 
synthesized a tosylic diaryliodonium salt strategy that was similar to that developed in the 
DiMagno lab93 (Scheme 1-13). 
 
 
The former synthetic approach includes strong acid that would interfere with the 
acid-labile protecting groups. The methodology developed in our lab requires a Lewis 
acid, avoiding deprotection of the compounds. I attempted to use the DiMagno approach, 
however, in my hands, the reaction was unsuccessful in synthesizing an iodonium salt at 
the C-2 position of indole. Because of the unsuccessful reaction, there was a need to 
develop a new heavy-metal and Brønsted-acid-free synthetic approach. 
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Scheme 1-13 A) Suna approach to synthesis of indole diaryliodonium approach 
B) General DiMagno approach to synthesis of diaryliodonium salts 
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Magnesium offers an interesting alternative to the heavy metals commonly used 
in the synthesis of diaryliodonium salts. Previous work in the DiMagno lab94 showed that 
lithium is too reactive of a metal for diaryliodonium salt synthesis, while zinc is a 
cumbersome reaction. Diaryliodonium salts from tin, copper, and platinum reagents are 
hard to purify and have toxicity problems. Magnesium is less reactive than lithium, and 
its side products are water-soluble. 
 Grignard reagents are well known to anyone in organic synthesis from the time 
they are undergraduate students. Generally, they are known to add into carbonyl groups 
or act as bases, limiting their usefulness in complex organic syntheses. They can 
however, undergo transmetalation reactions. Transmetalation Grignard reactions at low 
temperatures have low reactivity towards protecting groups,95 and are therefore more 
useful for synthetic chemistry than standard Grignard reactions. Generally, 
transmetalation reactions are done with Iron,96 Cadmium, or Cuprate97 catalysts or co-
reagents. Knochel,95 however, published reactions of Grignard transmetalation without 
any co-reagents in highly functionalized, Grignard-sensitive molecules. 
1.2.3 Structures of Novel Grignard 
In our group, Dr. Bao Hu first discovered the usefulness of Grignard reagents for 
synthesis of diaryliodonium salts when trying to oxidize unreactive iodo arenes. After 
many failed attempts, Dr. Hu discovered that transmetalation with iso-propyl magnesium 
chloride and coupling with (4-methoxyphenyl)-λ3-iodanediyl diacetate provided the 
desired diaryliodonium salt. I modified his approach by using fewer equivalents for 
longer periods of time (Scheme 1-14). Possibly most interesting was the high functional 
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group stability of this reaction. By cooling the reaction to -78°C, traditionally Grignard 
sensitive groups like amides and esters were unaffected by the reaction. 
 
 
Because of my failed attempts at oxidizing 2-iodo indole, I attempted to perform 
the transmetalation on tert-butyl 3-((4-methoxyphenyl)(((trifluoromethyl)sulfonyl)oxy)-
λ3-iodanyl)-1H-indole-1-carboxylate (Scheme 1-15). 
 
 
 After some optimization, I was able to synthesize the desired salt. I continued 
with a thermolysis using TBAN3 to test nucleophile selectivity. The nucleophile 
selectivity surprisingly favored functionalization of anisole 9:1 (Figure 1-6). This is 
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Scheme 1-14 Hu general synthetic strategy of diaryliodonium salts via a Grignard 
intermediate 
Scheme 1-15 Synthesis of tert-butyl 3-((4-methoxyphenyl) 
(((trifluoromethyl)sulfonyl)oxy-λ3-iodanyl)-1H-indole-1-carboxylate via Grignard 
transmetalation 
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easiest to quantify in the crude NMR by comparing the singlet peaks of the C-1 position 
of both indoles.  
 
  
 
 Nucleophile selectivity relies on the electron-richness of the directing group. In 
this case, the results show the indole was more electron-rich than the anisole, limiting the 
functionalization capabilities of tert-butyl 3-((4-methoxyphenyl) 
(((trifluoromethyl)sulfonyl)oxy-λ3-iodanyl)-1H-indole-1-carboxylate. To try to shift the 
electronics more towards indole functionalization, I attempted two more electron-
withdrawing protecting groups: acetyl and tosyl.  
I synthesized 1-(3-iodo-1H-indol-1-yl)ethan-1-one from 2-iodoindole (Scheme 1-
16). Compound 58 had no synthetic precedence, so I modified the Boc protection using 
N
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Figure 1-6 Crude Thermolysis of tert-butyl 3-((4-methoxyphenyl) 
(((trifluoromethyl)sulfonyl)oxy-λ3-iodanyl)-1H-indole-1-carboxylate 
N
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acetic anhydride, DMAP, and triethylamine, neat. For the formation of (1-acetyl-1H-
indol-3-yl)(4-methoxyphenyl)-λ3-iodanyl trifluoromethanesulfonate, I did the 
transmetalation with iPrMgCl at -78°C, and quenched with a THF solution of (4-
methoxyphenyl)-λ3-iodanediyl diacetate at -78°C before warming to room temperature. 
After workup, I did an ion exchange with sodium triflate to get the desired product. 
 
 
 I attempted the thermolysis of (1-acetyl-1H-indol-3-yl)(4-methoxyphenyl)-λ3-
iodanyl trifluoromethanesulfonate with 1-ethoxy-1-hydroxy-2-
(hydroxy(oxo)ammonio)propan-2-ide, which was the functional group for Kempinger’s 
work. What I found was that the acetate diaryliodonium salt was not stable under 
thermolysis conditions, and a large amount of 4-iodoanisole was produced (Figure 1-7). 
Multiple attempts at the thermolysis reaction showed the same results, and I decided to 
move forward with the more electron-withdrawing tosyl. 
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Scheme 1-16 Synthesis of (1-acetyl-1H-indol-3-yl)(4-methoxyphenyl)-λ3-iodanyl 
trifluoromethanesulfonate 
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Synthesis of (4-methoxyphenyl)(1-tosyl-1H-indol-3-yl)-λ3-iodanyl 
trifluoromethanesulfonate proceeded similarly to the Boc- and acetyl-protected 
compounds (Scheme 1-17). Indole was iodinated with KOH/I2, and then protected with 
sodium hydroxide and tosyl chloride in dichloromethane98. For the formation of (4-
methoxyphenyl)(1-tosyl-1H-indol-3-yl)-λ3-iodanyl, I did the transmetalation with 
iPrMgCl at -78°C and quenched with a THF solution of (4-methoxyphenyl)-λ3-iodanediyl 
diacetate at -78°C before warming to room temperature. After workup, I did an ion 
exchange with sodium triflate to get the desired product. 
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Figure 1-7 Crude thermolysis of (1-acetyl-1H-indol-3-yl)(4-methoxyphenyl)-λ3-iodanyl 
trifluoromethanesulfonate with 1-ethoxy-1-hydroxy-2-(hydroxy(oxo)ammonio)propan-2-ide 
Scheme 1-17 Synthesis of (4-methoxyphenyl)(1-tosyl-1H-indol-3-yl)-λ3-iodanyl 
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 I attempted the thermolysis with 1-ethoxy-1-hydroxy-2-
(hydroxy(oxo)ammonio)propan-2-ide to synthesize a quaternary tryptophan (Figure 1-8). 
The thermolysis showed better selectivity than the previous compounds. I was able to 
achieve approximately a 45% yield of the desired functionalized indole, (4-
methoxyphenyl)(1-tosyl-1H-indol-3-yl)-λ3-iodanyl. However, I also had a 55% yield of 
the functionalized anisole.  
 
 
With the poorly-selective thermolysis data, continuing forward to attempt to 
synthesize a salt for the quaternary amino acid project was not feasible. The C-2 position 
of indole is too electron rich for selective thermolysis without a stronger directing group.  
Finally, I wanted to synthesize an indole with a bromide to test the selectivity of 
the Grignard transmetalation (Scheme 1-18). The brominated-quaternary tryptophan is a 
known reverse transcriptase inhibitors.85 I began with the iodination 5-bromoindole,99 62, 
with KOH/I2 63 and protected with tosyl chloride/NaOH 64. I performed the 
Figure 1-8 Crude thermolysis of (4-methoxyphenyl)(1-tosyl-1H-indol-
3-yl)-λ3-iodanyl with 1-ethoxy-1-hydroxy-2-
(hydroxy(oxo)ammonio)propan-2-ide 
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transmetalation with iPrMgCl and quenched with (4-methoxyphenyl)-λ3-iodanediyl 
diacetate to give (5-bromo-1-tosyl-1H-indol-3-yl)(4-methoxyphenyl)-λ3-iodanyl 
trifluoromethanesulfonate 65. After workup, I did an ion exchange with sodium triflate. 
The transmetalation was completely selective, and no diaryliodonium salt was detected at 
the C-5 position. With a successful thermolysis, the synthesis of a quaternary tryptophan 
via diaryliodonium salt could also be used to again form a diaryliodonium salt at the C5 
position. 
 
 
1.3.1 Conclusion 
 Indoles are of synthetic interest because of their electron rich properties and their 
vast uses in nature. By synthesizing a diaryliodonium salt on the benzene ring, 
diaryliodonium salts can be formed from drugs, neurotransmitters, psychedelic drugs, and 
many others. Indole diaryliodonium salts can be used in PET to study the metabolism of 
these tracers. Because of the electron-rich benzene ring of the indole, synthesis of a 
diaryliodonium salt will require an electron-withdrawing protecting group to be used for 
functionalization chemistry. Groups such as tosyl or acetate can be explored using the 
presented syntheses. 
Scheme 1-18 Synthesis of(5-bromo-1-tosyl-1H-indol-3-yl)(4-methoxyphenyl)-λ3-
iodanyl trifluoromethanesulfonate 
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 More interesting however, is the formation of diaryliodonium salts at the C-2 
position. The electronics are too strong for selective functionalization of indole with 
anisole. However, it can be explored as alternative directing group for electron rich 
molecules. The electron-rich molecules presented in this chapter are stable, and may be 
explored in the future. 
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1.3.2 Experimentals 
 
tert-butyl 5-((hexafluoro-λ7-phosphanyl)(4-methoxyphenyl)-λ3-iodanyl)-1H-indole-1-
carboxylate (via tert-butyl 5-iodo-1H-indole-1-carboxylate) (18) 
In a N2 charged glove box, F-TEDA-BF4 (134 mg, 0.38 mmol) was dissolved in 1 
mL CH3CN in a 2 mL vial. Trimethylsilyl acetate (100 mg, 0.76 mmol) in 1 mL CH3CN 
was added dropwise to the solution with swirling. The solution was added to a suspension 
of 100 mg (0.29 mmol) tert-butyl 5-iodo-1H-indole-1-carboxylate55 in 2 mL acetonitrile 
dropwise. The reaction mixture was placed in a 25 mL Schlenk flask charged with a 
magnetic stirbar, removed from the glove box, and stirred for 4 hours at 40 °C. The 
Schlenk flask was brought back into the glove box. Into the diacetate solution was added 
potassium (4-methoxyphenyl) trifluoroborate (62.3 mg, 0.29 mmol). Trimethylsilyl 
trifluoroacetate (49 mg, 0.29 mmol) was dissolved in 1 mL acetonitrile and added to the 
stirring solution dropwise. The reaction continued to stir for 30 minutes and was brought 
out of the glove box. The solution was transferred to a 50 mL round bottom flask. The 
solvent was removed via rotary evaporation. The resulting oil was dissolved in 10 mL 
dichloromethane and washed with 10 mL acetate buffer (NaOAc:HOAc = 0.5 M :0.5 M, 
pH = 5) and 15 mL DI water 3x. The organic layer was collected, dried with Na2SO4, and 
filtered. The filtrate was evaporated via rotary evaporation, and the oil was  brought up in 
acetonitrile and washed with pentanes. Solvent was removed.  To form the 
hexafluorophosphate salt, the trifluoroacetate salt was dissolved in 10 mL ethanol in a 50 
mL round bottom flask charged with a magnetic stirbar. Sodium hexafluorophosphate 
N
Boc
I
F6P
O
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(382 mg, 2.28 mmol),  was dissolved in 5 mL DI water and added dropwise to the stirring 
salt. The suspension was stirred for one hour at room temperature. Organic solvent was 
removed by rotary evaporation. The aqueous suspension was extracted with  10 mL 
dichloromethane 3x. The organic layers were combined, dried with Na2SO,, and filtered. 
The filtrate was evaporated via rotary evaporation and the residual oil was recrystallized 
from ethyl acetate/methyl tert butyl ether. (110 mg, 64%) 1H NMR (CD3CN, 700 MHz, 
25C):  8.37 (d, J = 1.8 Hz, 1 H), 8.2790 28 (d, J = 9.0 Hz, 1 H), 8.0293 03 (d, J = 9.2 
Hz, 2 H), 7.9312 (dd, J = 9.0, 1.9 Hz, 1 H), 7.81714 (d, J = 3.8 Hz, 1 H), 7.0632 (d, J = 
9.2 Hz, 2 H), 6.7600 (d, J = 3.8 Hz, 1 H), 3.8477 85 (s, 3 H), 1.6653 (s, 9 H). 13C NMR 
(CD3CN, 176 MHz, 25C):  164.2, 150.0, 139.3, 138.4, 137.7, 134.3, 130.6, 130.2, 
129.7, 119.0, 107.6, 107.5, 103.1, 86.3, 56.7, 28.2. 19F NMR (CD3CN, 276 MHz, 25C)  
-73.0 (d, J = -706.2 Hz, PF6
-, 6 F). HRMS (ESI) calculated for C20H21INO3
+ [M-PF6
-]+ 
450.0556, found 450.0568.  
 
 
tert-butyl 5-bromo-3-(2-((tert-butoxycarbonyl)amino)ethyl)-1H-indole-1-
carboxylate (27) 
 In a 100 mL round bottom flask charged with a magnetic stirbar, 2-(5-bromo-1H-
indol-3-yl)ethan-1-amine56 (943 mg, 3.962 mmol) was dissolved in 6.6 mL 
tetrahydrofuran. 6.6 mL of saturated sodium bicarbonate was added dropwise, and the 
solution was stirred vigorously until no bilayer remained. The solution was cooled to 
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0°C. (Boc)2O (1.037 g, 4.754 mmol) was dissolved in 4.75 mL tetrahydrofuran and added 
dropwise. The solution was stirred for two hours at room temperature. The solution was 
poured into a 100 mL separator funnel. The solution was allowed to separate, and the 
organic layer removed. The aqueous layer was extracted with ethyl acetate (3x 20 mL). 
The organic layers were combined and washed with DI water (3x 30 mL) and brine (1x 
30 mL). The organic layers were dried with Na2SO4, filtered, and solvent was removed 
via rotary evaporation. The yellow oil was dissolved in 40mL CH3CN and 
dimethylamino pyridine (0.2870 g, 2.2565 mmol) and triethylamine (2.740 g, 27.0786 
mmol) were added. The solution was cooled to 0°C and (Boc)2O (3.940 g,  18.0524 
mmol) was added. The solution was stirred for 18 hours at room temperature. The solvent 
was removed via rotary evaporation, and the crude oil was cleaned via flash 
chromotography (9:1 hexanes:ethyl acetate). The remaining colorless oil was dissolved in 
pentane and cooled in a freezer overnight to produce 1.840 g (80%) white crystals. 
1HNMR (CD3CN, 400 MHz, 25C):  8.01(d, J = 8.8, 1 H), δ7.76 (s, 1 H), δ7.46 (s, 1 H), 
δ 7.43 (d, J = 8.8 1 H), δ 3.84 (t, J = 6.7, 2 H), δ 2.95 (t, J = 6.7, 2 H), δ 1.44 (s, 9 H), δ 
1.39 (s, 18 H) 13C NMR (276 MHz): 152.7, 149.5, 134.5, 132.6, 127.3, 134.7, 122.0, 
117.2, 116.9, 116.1, 84.1, 82.6, 46.5, 34.3, 28.4, 28.2, 24.7, 22.5, 14.3 HRMS (ESI) 
calculated for C25H35BrN2O6 563.1678 found  563.1553  
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tert-butyl 3-(2-((tert-butoxycarbonyl)amino)ethyl)-5-((hexafluoro-λ7-phosphanyl)(4-
methoxyphenyl)-λ3-iodanyl)-1H-indole-1-carboxylate (30) 
In a 100 mL Schlenk flask charged with magnetic stirbar, tert-butyl 3-(2-((tert-
butoxycarbonyl)amino)ethyl)-5-(trifluoro-λ4-boranyl)-1H-indole-1-carboxylate, 
potassium salt (2.0 g, 3.5321 mmol) and (4-methoxyphenyl)-λ3-iodanediyl diacetate (1.24 
g, 3.5321 mmol) were dissolved in 30 mL CH3CN. TMSTFA (0.600 g, 3.5321 mmol) 
was dissolved in 5 mL CH3CN and added dropwise to the stirring solution. The solution 
was stirred for 1 hour at room temperature. The solution was transferred to a 100 mL 
found bottom flask. The solvent was removed by rotary evaporation, and the remaining 
oil was again dissolved in 10 mL CH3CN with a magnetic stirbar. Sodium 
hexafluorophosphate (3.527 g, 21.926 mmol) was dissolved 10 mL DI water and was 
added to the stirring solution dropwise. The solution was stirred for two hours at room 
temperature. Acetonitrile was removed via rotary evaporation, and the aqueous 
suspension was extracted with dichloromethane (3x 15 mL). The organic layers were 
combined, dried with Na2SO4, filtered and solvent removed via rotary evaporation. The 
remaining oil was recrystallized from ethyl acetate/ether. 1HNMR (CD3CN, 400 MHz, 
25C): δ 8.37 (d, J = 1.8, 1 H), δ 8.21 (d, J = 8.9, 1 H), δ 8.02 (d, J = 9.1, 2 H), δ 7.92 
(dd, J = 8.9, 1.9), δ 7.57 (s, 1 H) δ 7.02 (d, J = 9.2, 2 H) δ 3.85 (t, J = 6.7, 2 H), δ 3.81 (s, 
3 H) δ 2.98 (t, J = 6.7, 2 H), δ 1.62 (s, 9 H) δ 1.31 (s, 18 H) 13C NMR (276 MHz): 164.5, 
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153.8, 138.6, 134.9, 131.2, 128.8, 128.0, 120.1, 119.4, 119.0, 117.9, 107.5, 103.4, 86.5, 
83.3, 57.0, 49.8, 46.9, 28.5, 28.4, 28.4, 27.6, 25.2 HRMS (ESI) C32H42N2O7I, calculated 
393.2037, found 393.2046 
 
1-(3-iodo-1H-indol-1-yl)ethan-1-one (62) 
 In a 100 mL round bottom flask charged with magnetic stirbar, indole (0.500 g, 
4.268 mmol) and crushed potassium hydroxide (0.599 g, 10.6701 mmol) were dissolved 
in dimethylformamide (0.5 M, 10 mL). The reaction was stirred at room temperature for 
20 minutes. Iodine (1.086 g, 4.268 mmol) was dissolved in 5 mL dimethylformamide and 
added to indole solution. After 45 minutes, the reaction was poured over DI water and 
filtered.  
 The precipitate was dried in vacuo in a 50 mL round bottom flask charged with a 
magnetic stirbar. 2.2 mL of acetic anhydride, 4-dimethyl aminopyridine (0.028 g, 0.2227 
mmol) and triethylamine (0.72 mL) were added. The reaction was stirred overnight. 
Solvent was removed in vacuo and the product was purified by column chromatography 
(9:1 hexanes:ethyl acetate). (2.250 g, 74.2% over 2 steps). 1H NMR (CD3CN, 400 MHz, 
25C):  8.35 (d, J = 7.8, 1 H), 7.83 (s, 1 H), 7.38 (m, J = 8.3, 3 H), 2.58 (s, 3 H). 13C 
NMR (CD3CN, 176 MHz 25C):  169.8, 136.0, 133.0, 132.3, 126.9, 125.1, 122.1, 117.1, 
67.0, 24.4. HRMS (ESI) calculated for C10H8NOI: 284.9651, found 284.9659. 
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(1-acetyl-1H-indol-3-yl)(4-methoxyphenyl)iodonium trifluoromethanesulfonate (63) 
 Under inert N2 atmosphere in a 50 mL Schlenk flask charged with a stirbar, 1-(3-
iodo-1H-indol-1-yl)ethan-1-one (1.0 g, 3.5091 mmol) was dissolved in 2 mL dry THF. 
The solution was cooled to -78°C, and iPrMgCl (2.0 M, 5.2635 mmol, 2.63 mL) was 
added. The solution was stirred for 5 minutes at -78°C. The solution was added quickly to 
a suspension of (4-methoxyphenyl)-λ3-iodanediyl diacetate (3.5807 g, 10.5274 mmol) in 
3 mL dry THF in a 50 mL Schlenk flask. The solution was stirred at -78 C for 10 
minutes. The ice bath was removed and the solution was stirred for 1 hour at room 
temperature.  
 The solvent was removed in vacuo over 18 hours. The yellow oil was dissolved in 
5 mL methanol. Sodium trifluoromethane sulfonate (2.470 g, 7.0182 mmol) was 
dissolved in 5 mL DI water and added dropwise with stirring. The solution was stirred for 
1 hour and the organic solvent was removed by rotary evaporation. The aqueous solution 
was extracted 3x with 10 mL dichloromethane. The organic layers were combined, dried 
with Na2SO4, and filtered. The filtrate was dried in vacuo. The crude oil was 
recrystallized from ethyl acetate/ether. (1.063 g, 56%) 1H NMR (CD3CN, 700 MHz, 
25C):  8.60 (s, 1 H), 8.47 (d, J = 8.3, 1 H), 8.05 (d, J = 9.1, 2 H), 7.69 (d, J = 7.8, 1 H), 
7.55 (dd, J = 7.7, 1 H), 7.51 (dd, J = 7.6, 1 H), 7.03 (d, J = 9.2, 2 H), 3.82 (s, 3 H), 2.72 
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(s, 3 H) 13C NMR (276 MHz): δ 170.3, 164.2, 138.0, 137.5, 136.1, 129.0, 128.3, 126.4, 
120.4, 119.0, 118.0, 103.2, 85.1, 56.8, 24.4 HRMS (ESI) calculated for C17H15NO2I: 
392.0148, found 392.0161. 
 
(4-methoxyphenyl)(1-tosyl-1H-indol-3-yl)iodonium trifluoromethanesulfonate (75) 
 Under inert N2 atmosphere in a 50 mL Schlenk flask charged with a stirbar, 3-
iodo-1-tosyl-1H-indole98 (0.500g, 1.2596 mmol) was dissolved in 2 mL dry THF. The 
solution was cooled to -78°C, and iPrMgCl (2.0 M, 1.8894 mmol, .95 mL) was added 
dropwise. The solution was stirred for 5 minutes at -78°C, and cannulated into a 
suspension of (4-methoxyphenyl)-λ3-iodanediyl diacetate in dry THF at -78°C. The 
solution was stirred for 10 minutes at -78°C. The ice bath was removed and solution was 
stirred for 1 hour at room temperature.  
The solvent was removed in vacuo, and the remaining yellow oil was dissolved in 
5 mL methanol. Sodium trifluoromethane sulfonate (1.300 g, 7.5574 mmol) was 
dissolved in 5 mL DI water and added dropwise. The solution was stirred for 1 hour at 
room temperature. The organic solvent was removed by rotary evaporation. The 
remaining aqueous solution was extracted with 10 mL dichloromethane 3x. The organic 
layers were combined, dried with Na2SO4, and filtered. The filtrate was dried in vacuo, 
and the remaining crude oil was recrystallized from ethyl acetate/ether. 1H NMR 
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(CD3CN, 700 MHz, 25C):  8.59 (s, 1 H), 8.02 (d, J = 8.4, 1 H), 7.98 (d, J = 9.0, 2 H), 
7.87 (d, J = 8.3, 2 H), 7.60 (d, j = 7.9, 1 H), 7.50 (dd, J = 7.8, 1 H), 7.43 (dd, J = 7.6, 1 
H), 7.35 (d, J = 8.1, 2 H), 6.96 (d, J = 9.0, 2 H), 3.79 (s, 3 H), 2.34 (s, 3 H). 13C NMR 
(CD3CN, 176 MHz, 25C):  164.2, 148.3, 138.3, 138.0, 136.5, 135.0, 134.4, 131.6, 
129.5, 129.4, 128.4, 128.3, 128.2, 126.6, 119.0, 103.6, 86.5, 56.7, 21.7. HRMS (ESI) 
calculated for C22H19NO3SI 504.0106, found 504.0114 
 
(5-Bromo -1-tosyl-1H-indol-3-yl)(4-methoxyphenyl)iodonium 
hexafluorophosphate(V) (79) 
Under inert N2 atmosphere in a 50 mL Schlenk flask charged with a stirbar, 5-
bromo-3-iodo-1-tosyl-1H-indole99 (2.0 g, 4.21167 mmol) was dissolved in 2 mL dry 
THF. The solution was cooled to -78°C, and iPrMgCl (2.0 M, 6.3175 mmol, 3.16 mL) 
was added dropwise. The solution was stirred for 10 minutes at -78°C. The Grignard 
solution was cannulated into a 50 mL Schlenk flask charged with magnetic stirbar and a 
solution of (4-methoxyphenyl)-λ3-iodanediyl diacetate (2.865 g, 8.4233 mmol) in 2 mL 
THF at -78°C. The solution was stirred for ten minutes at -78°C. The ice bath was 
removed, and the solution was allowed to stir for 1 hour at room temperature.  
The solvent was removed in vacuo, and dissolved in 5 mL methanol. Sodium 
trifluoromethane sulfonate (4.34 g, 25.27 mmol) was dissolved in 5 mL DI water and 
added dropwise. The solution was stirred for 1 hour at room temperature. The organic 
N
Ts
I
Br
O
OTf
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solvent was removed by rotary evaporation. The remaining aqueous solution was 
extracted with 3x with 10 mL dichloromethane. The organic extractions were combined, 
dried with Na2SO4, and filtered. The filtrate solvent was removed  in vacuo, and the 
remaining crude oil was recrystallized from ethyl acetate/ether. 
 8.58 (s, 1H), 7.99 (d, J = 9.1 Hz, 2 H), 7.94 (d, J = 8.9 Hz, 1H), 7.87 (d, J = 8.5 Hz, 2 
H), 7.85 (d, J = 1.8 Hz, 1H), 7.61 (m, J = 3.6, 1.7 Hz 1 H),  7.37 (d, J = 8.2 Hz, 2 H), 6.99 
(d, J = 9.2 Hz, 2 H), 3.81 (s, 3 H), 2.36 (s, 3 H). 13C NMR (276 MHz):  164.1, 148.5, 
139.3, 138.1, 137.7, 134.2, 131.6, 131.2, 131.0, 128.4, 123.9, 119.0, 117.6, 116.8103.9, 
85.3, 56.7, 21.7. HRMS (ESI) calculated for C22H19INO3S 581.9236, found 581.9233 
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CHAPTER 2 
TOWARDS THE DEVELOPMENT OF POLYMERS FOR DIARYLIODONIUM 
SALT THERMOLYSIS FOR USE IN POSITRON EMISSION TOMOGRAPHY  
2.1 Introduction of Resins for PET  
A radiotracer’s success is dependent on its binding to a target and visibility on a 
PET scan. Binding and visibility can be improved by other factors like purity, 
enantiopurity, and time of synthesis. Purity and time of synthesis can be improved by 
manipulation of protecting groups and synthetic strategies before radiosynthesis.  
Radiochemical yield (RCY) is the yield of radiochemical separation divided by 
the activity originally present.100 Specific activity is the activity per set amount of 
nucleotide.100 These two values are most commonly used to discuss the usefulness of a 
radiotracer. While some commercial syntheses are used with radiochemical yields of 
under 10%,101-103 more successful syntheses have greater than a 50% yield.104,105 Factors 
like time of synthesis and purity play a large part in yields. Shorter syntheses result in 
lower decay of the radioisotopes, and more pure compounds require less time after 
introduction of the radionucleotide. 
To optimize radiochemical yields and specific activity, I developed methodology 
that could decrease time of synthesis and increase purity. I planned to do this by 
functionalizing diaryliodonium salts on a resin as a precursor for PET.  
[18F]-Fluorine is synthesized by bombarding H2
18O with a high-energy proton 
beam.106 Protons displace the 18O neutrons from the nucleus, which produces an aqueous 
18F-. The fluoride anion is trapped on an exchange resin to remove excess water. The 
fluoride is coordinated to a cryptand, usually 1,10-diaza-4,7,13,16,21,24-
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hexaoxabicyclo[8.8.8]hexacosane (Kryptofix). Water is removed by distillation with an 
apolar aprotic solvent such as acetonitrile. The tracer is then introduced. For the 
DiMagno group, the tracer is a diaryliodonium salt. After thermolysis, the products are 
purified. The products are loaded onto a silica separation pack, the reactor vial is rinsed, 
and the separation pack is eluted back into the reactor vial. Solvent is evaporated, and the 
products are deprotected, neutralized and purified by HPLC. The purification process 
should give a pure product, but may take upwards of an hour to complete. The main issue 
using diaryliodonium salts for radiofluorination is dilution of the products of the 
thermolysis reaction. Up to 3 side products are formed and require purification after 
introduction of the radionucleotide. By using a resin, all side products from thermolysis 
(Figure 1-4 in Chapter 1) would remain on the resin, and theoretically only the 
functionalized tracer would be washed off.  
Synthesis of iodine (III) on resins have been successfully accomplished for use as 
oxidants107,108 and for the synthesis of heterocycles.109 Polymer-supported hypervalent 
iodine reagents are useful in the pharmaceutical and agrochemical industries because of 
their low toxicity and high yields.110 Phenyliodine(III) diacetate was the first hypervalent 
iodine compound synthesized on a polymer-support by Chen in 1994.111 Since then, 
polymer-supported iodine(III) compounds have been vastly used for oxidation in a wide 
variety of solvents, including water112 and methanol,113 proving their stability and 
usefulness to a broad spectrum of reagents.  
Fewer syntheses have been accomplished for diaryliodonium salts on polymer 
support. Chen published syntheses114 of diaryliodonium salts used for functionalized of 
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Carbon and Sulfur ions. Their standard synthesis (Scheme 2-1) included oxidation by 
acetic acid and coupling with a functionalized arene.  
 
 Knowing that diaryliodonium salts could be synthesized on a polymer, I believed 
we could use DiMagno methodology to synthesize diaryliodonium salts with similar 
success to our solid-state syntheses.  
An ideal synthesis of a functionalized solid-phase resin would need to be 
relatively simple, efficient, and scalable. We chose to begin with the Wang resin because 
it met these criteria. The Wang resin is commercially available and often used on a large 
scale for peptide synthesis.115 It is also useful because of its easy decoupling by 
trifluoroacetic acid to show the yield of labeling.116 
The commercial synthesis of the Wang Resin (Scheme 2-2) begins with the 
coupling polystyrene with chloromethyl styrene. This gives the commercially Merrifield 
resin. The Merrifield resin is then coupled with 4-(hydroxymethyl)phenol to give Wang 
Resin.117 
Polymer I
AcOOH
Polymer I
OAc
OAc
R
Polymer I
H2SO4
HSO4
-
R1
R2
CHO
OH
PdCl2/LiCl, Na2CO3
R1
R2
O
ROH
+ Polymer I
Scheme 2-1 Chen Synthesis and Thermolysis of Polymer-Supported 
Diaryliodonium Salts 
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 Synthesis of the Wang Resin from Merrifield resin is not quantitative, and 
remaining chloride ions are present on the resin. The remaining benzyl chloride can later 
undergo SN2 reaction with the radioactive 
18F- source, and therefore has to be exchanged 
prior to synthesis. To remove all remaining chloride ions, I began my synthesis by “pre-
treating” the Wang resin with refluxing potassium hydroxide/water. I then coupled the 
desired substrate by Mitsunobu esterification (Scheme 2-3). To accommodate the 
reaction, I synthesized each of the substrates with a terminal carboxylic acid.  
 
 
 After coupling each substrate onto the resin, I needed to cap any remain terminal 
alcohols groups. I esterified all the benzyl alcohols by stirring in acetic anhydride. 
 
OH
HO R'
O PPh3
DIAD
THF 
0-> RT o/n
+ O
R R
R'
O
Scheme 2-2 Synthesis of Wang Resin from Polystyrene 
Scheme 2-3 General Mitsunobu Procedure for Functionalizing Wang Resin 
Polystyrene 
Merrifield Resin 
Wang Resin 
chloromethyl
styrene
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2.2 Synthesis of Aniline Test Compound and Aniline Based Wang Resin 
I first chose an aniline-based moiety because of its simplicity of synthesis. 
Synthesis (Scheme 2-4) began with the iodination of N-methyl aniline118 66 with 
saturated bicarbonate/iodine in dichloromethane to give 67. I then protected the 
moderately unstable aniline with glutaric anhydride and catalytic triethylamine in 
tetrahydrofuran to give the desired aniline 68 with terminal carboxylic acid in 62% yield. 
To mock the Wang resin, I used benzyl alcohol to synthesize the test compounds for 
Mitsunobu esterification.  To synthesize 69, I used the Mitsunobu esterification with 
triphenyl phosphine and diisopropyl azodicarboxylate neat. I oxidized 69 with 
SelectfluorTM and TMSOAc for 4 hours at 40°C and then coupled with trifluoro(phenyl)-
λ4-borane, potassium salt to successfully synthesize benzyl 5-((4-((4-
methoxyphenyl)(((trifluoromethyl)sulfonyl)oxy)-λ3-iodanyl)phenyl)(methyl)amino)-5-
oxopentanoate 70. The successful synthesis of 70 and subsequent thermolysis of the 
aniline test compound proved that synthesis of this aniline moiety on a resin should be 
hypothetically possible.  
 
NH
Sat. NaHCO3
DCM, I2
Quantitative
NH
I
Cat. Et3N
Glutaric Anh.
THF
62%
N
I
O
OH
O
Benzyl Alcohol
DIAD
PPh3
0°C -> RT o/n
78%
N
I
O
O
O
1. Selectfluor
TMSOAc
4 hours, 40°C
95+% conv.
2. TMSTFA
BF3K
O
N
I
O
O
O
OTf
O
66 67 68 69
70
58%
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I continued by using the Mitsunobu reaction to couple 5-((4-
iodophenyl)(methyl)amino)-5-oxopentanoic acid to the Wang resin (Scheme 2-5). Using 
an excess of Selectfluor TM and TMSOAc, I oxidized the resin, washed away the excess 
oxidant, and coupled with TMSTFA and trifluoro(phenyl)-λ4-borane, potassium salt. I 
chose the phenyl to test the electronics of the resin. We know that aniline is less electron-
rich than anisole, however, I did not know the directing-group ability of the aniline 
compared to less electron-rich compounds such as phenyl. 
 
 
I exchanged the trifluoroacetate counterion to triflate. To do this, I passed through 
TMSOTf in acetonitrile until no trifluoroacetate was detected by NMR of the flitrate. I 
proceeded with the thermolysis reaction with tetra butylammonium bromide, which after 
2 hours at 100°C showed incomplete selectivity in benzene solvent.  
 
Scheme 2-4 Synthesis of benzyl 5-((4-((4-methoxyphenyl)(2,2,2-trifluoroacetyl)-λ3-
iodanyl)phenyl)(methyl)amino)-5-oxopentanoate 
Scheme 2-5  Synthesis of Aniline Diaryliodonium Salt on Wang Resin 
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 In the small quantities that are used in an NMR reaction of the resin, it was not 
possible to quantify the exact ratio. However, comparison with the NMRs of both 
bromobenzene and iodobenzene, it was confirmed that both of these were present in the 
filtrate. Because of the incomplete selectivity, I knew that continuing with the aniline 
resin would not be useful due to its incomplete selectivity for even electron poor 
substrates. 
2.3 Synthesis of Anisole Test Compound and Anisole Based Wang Resin 
Because of the lack of selectivity in the aniline resin, I carried forward with the 
more electron rich anisole. Anisole is the standard electron-rich directing group in the 
DiMagno lab (Scheme 2-6). I began with the etherification of 4-iodo phenol 76 with 
ethyl-4-bromobutanoate 77119 to give 4-(4-iodophenoxy)butanoic acid 78. Esterification 
by Mitsunobu reaction with benzyl alcohol gave the desired test compound benzyl 4-(4-
iodophenoxy)butanoate 79. Oxidation and coupling of the anisole compound with 
trifluoro(4-methoxyphenyl)-λ4-borane, potassium salt, potassium salt gave the desired 
benzyl 4-(4-((4-methoxyphenyl)(2,2,2-trifluoroacetyl)-λ3-iodanyl)phenoxy)butanoate. 
Figure 2-1 Thermolysis of Aniline Resin with TMABr 
A 
A A 
A 
B 
B 
B 
A 
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Because we knew that this resin was equivalent anisole, our standard nucleophile 
director for diaryliodonium salt thermolysis, I decided to try the reaction using the 
pharmaceutically relevant compound metaiodobenzyl guanidine (MIBG) on the Wang 
resin. MIBG will be discussed in greater detail later in chapter 2. The MIBG 
diaryliodonium salt had been previously synthesized and radiofluorinated and 
radioiodinated by Dr. Bao Hu from our group. Using his compound, tert-butyl (E)-(((tert-
butoxycarbonyl)imino)(3,5-dimethyl-4-oxo-1,3,5-triazinan-1-yl)methyl)(3-(trifluoro-l4-
boranyl)benzyl)carbamate, potassium salt 82, we hoped to anchor it onto a resin, making 
an already highly desirable radiotracer even more useful. 
I
OH
Br
O
O
1.
K2CO3
1 hr 100°C
2. 1M KOH/MeOH RT o/n
I
O
OH
O
Benzyl Alcohol
DIAD
PPh3
0°C -> RT o/n
I
O
O
O
1. Selectfluor
TMSOAc
4 hours
95+% conv.
2. TMSTFA
BF3K
I
O
O
O
O
OTf
76
90
77 78
79
O
Scheme 2-6 Synthesis and functionalization of benzyl 4-(4-((4-methoxyphenyl)(2,2,2-
trifluoroacetyl)-λ3-iodanyl)phenoxy)butanoate 
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 I did a Mitsunobu esterification using Wang resin and 4-(4-iodophenoxy)butanoic 
acid 77. I oxidized the resin with an excess of TMSOAc and SelectfluorTM, washed it 
with acetonitrile, and coupled it with tert-butyl (E)-(((tert-butoxycarbonyl)imino)(3,5-
dimethyl-4-oxo-1,3,5-triazinan-1-yl)methyl)(3-(trifluoro-λ4-boranyl)benzyl)carbamate, 
potassium salt 82. I tried passing dilute TMSOTf in acetonitrile like I had done with the 
aniline resin, however, the anisole resin decomposed. Instead, I stirred the resin in an 
aqueous solution of sodium triflate until there was complete exchange by NMR of the 
filtrate (Scheme 2-7).  
 I did a thermolysis of the resin with TMABr overnight at 100°C. What I found 
was that the only MIBG product observed was the brominated product. However, there 
was also other observable side products presumed to be from the resin (Figure 2-2). 
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Scheme 2-7 Functionalization of Wang Resin with MIBG diaryliodonium salt 
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 After multiple attempts with this reaction, there seemed to be no solution for the 
extra-cleaved products. Because of the issue, another synthetic strategy needs to be 
pursued. 
2.4 Synthesis of Anisole Based Merrifield Resin 
The Merrifield resin, as previously discussed, is synthesized by reacting 
polystyrene with chloromethyl styrene. By using this resin, my synthesis was simplified 
because it was only necessary to do an SN2 reaction with 4-iodophenol (Scheme 2-8). I 
stirred the Merrifield resin, 4-iodophenol, potassium carbonate, and potassium iodide in 
Figure 2-2 Thermolysis of Wang Resin with MIBG diaryliodonium salt 
A B 
B 
B 
B
A 
A A 
A 
A A 
A A 
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DMF, and after 72 hours at 120°C, I filtered and washed the resin. I capped the resin by 
refluxing methanol with potassium carbonate. 
 
 
 The Merrifield resin has potential moving forward as a resin option. We believed 
that the side products produced by the Wang Resin was from cleaving across the ester 
bond, which is not present in the Merrifield Resin. 
2.5 Introduction of Meta-iodobenzyl Guanidine and Future Directions 
 MIBG is a radiolabelled molecule similar to noradrenaline (Figure 2-3). It is taken 
up through the neuronal uptake I system and is stored in the noradrenergic neuorsecretory 
granules, also similar to noradrenaline.119 It is well-known that its I-123 and I-131 
radioisotopes can be used to image adrenergic tissues,120 pheochromocytomas,121 and 
neuroblastomas.122 It has largely overtaken CT scans and MRI scans for detecting these 
tumors. CT scans can detect tumors 2 cm in diameter, however, this leaves a substantial 
number of smaller, and often-malignant tumors undetected.120 (123/125/131I) MIBG is used 
and treat to detect these tumors.  
 
 
Cl
R
I
OH
K2CO3, KI
120°C, 72 hrs
O
R
I
Scheme 2-8 Functionalization of Merrifield Resin 
Figure 2-3 MIBG and Noradrenaline 
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 131I-MIBG was first developed for the imaging of the sympathetic innervation of 
the heart123 and as well as the adrenal medulla.120 In 1985, Shapiro124 showed that in large 
doses 131I-MIBG could also be used for tumor regression in malignant 
pheochromocytomas. Approximately 90% of I-131 decay is beta radiation, which causes 
tissue damage to the cells it penetrates as well as cells up to several millimeters away. It 
is also visible by imaging techniques in large doses because the remaining 10% of decay 
is via gamma radiation. 123I-MIBG is used in SPECT-CT125 for diagnosis of 
neuroblastoma. 18F-MFBG has also become of recent interest to our lab126 because of its 
low half-life and superior imaging quality127-129. 
Because of the large amount of work in our lab and the interest that is growing in 
MIBG, the future goal is to functionalize MIBG on a finalized resin. Previous work by 
Dr. Hu in our lab125 guided my synthesis of a boronate precursor of the desired salt. Dr. 
Hu originally synthesized the tetrakis-Boc protected diaryliodonium salt, but was only 
able to obtain a 95% yield that was unable to be purified by recrystallization126. The 
“greasiness” of this compound makes it unable to be used as a radiochemical precursor. 
Because of this, 82 was synthesized for non-polymer use. However, while pursuing these 
compounds on a polymer, I knew that recrystallization and purity would not be an issue, 
and that the tetra-kis Boc protected MIBG had a less harsh deprotection strategy. I chose 
to carry forward with a new synthesis of the 93, which had not previously been 
synthesized by our lab or others (Scheme 2-9). 
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The commercially available 1H-pyrazole-1-carboximidamide 86 was Boc 
protected to give tert-butyl (E)-(tert-butoxycarbonyl)(((tert-butoxycarbonyl)imino)(1H-
pyrazol-1-yl)methyl)carbamate 87.130 Using magnesium perchlorate hexahydrate, I did a 
single Boc deprotection for 88, followed by a coupling with (3-iodophenyl)methanamine 
hydrochloride126 to give 89. I then did a final Boc protection 90, synthesized the boronic 
ester using palladium catalysis 91, and fluorinated with potassium bifluoride 92. 
 Because of this work, future works can be done to synthesize an array of 
compounds on different resins. While I was unable to synthesize a resin with a 
pharmaceutically relevant compound on it, I did discover that oxidation by SelectfluorTM 
and TMSOAc and our thermolysis are possible. This has shown that this chemistry is 
very applicable for solid-phase work, and can be used in the future to even possibly 
design a radiosynthesis on a polymer. 
  
Scheme 2-9 Synthesis of tert-butyl ((λ2-azanylidene)(bis(tert-
butoxycarbonyl)amino)methyl)(3-(trifluoro-λ4-boranyl)benzyl)carbamate, potassium 
salt 
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2.5 Experimentals 
5-((4-Iodophenyl)(methyl)amino)-5-oxopentanoic acid 
 
N-methyl-4-iodo-aniline (21.75 g, 93.33 mmol) was dissolved in 95 mL of acetonitrile. 
Triethylamine (9.44 g, 93.33 mmol) and glutaric anhydride (15.97 g, 139.99 mmol) were 
added. The solution was stirred overnight at room temperature. The solvent was removed 
and then purified by column chromatography (80:20 hexanes:ethyl acetate). Glutaric 
anhydride was left over after purification, and the brown oil was purified by 
recrystallization (THF/Hexanes) to produce a white solid (25.4 g, 62%). 1H NMR 
(acetone, 700 MHz)  7.81 (d, J = 7.0, 2 H), 7.16 (d, J = 8.4 Hz, 2 H), 3.78 (s, 1 H), 3.20 
(s, 3 H), 2.26 (s, 2 H), 2.1413 (s, 2H), 1.807081 (, m, J = 6.61706 Hz, 2 H) 13C NMR 
(acetone-d6, 276 MHz, 25 C)  174.4, 172.0, 145.3, 139.4, 130.7, 69.3, 54.7, 27.3, 33.4, 
21.3. HRMS (ESI) calculated for C12H13INO3
- [M+Na]+ 369.9916, found 369.9922.  
 
benzyl Benzyl 5-((4-iodophenyl)(methyl)amino)-5-oxopentanoate 
 
5-((4-iodophenyl)(methyl)amino)-5-oxopentanoic acid (2.00 g, 5.40 mmol) and benzyl 
alcohol (0.64 g, 5.94 mmol), were dissolved in 25 mL dichloromethane. The solution was 
N OH
I
O O
N O
I
O O
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cooled to 0 °C. N,N'-Dicyclohexylcarbodiimide was dissolved in 10 mL dichloromethane 
and added dropwise. The solution was stirred at 10 minutes at 0 °C and at room 
temperature for one hour. The suspension was filtered and the mother liquor was washed 
with DI water (3x). The crude oil was purified by column chromatography (90:10 
hexanes:ethyl acetate). (1.98 g, 78%)  1H NMR (CDCl3, 700 MHz)  7.66 (d, J = 8.2 Hz, 
2 H) 7.29 (m, J = 9.6 Hz, 5 H), 6.86 (d, J = 7.3 Hz, 2 H), 5.01 (s, 2 H), 3.17 (s, 3 H), 2.31 
(s, 2 H), 2.07 (s, 2 H) 1.88 (s, 2 H); 13C NMR (CDCl3, 276 MHz,)  172.8, 171.7, 143.6, 
135.9, 129.2, 128.5, 128.1, 66.0, 37.2, 33.3, 33.0, 25.7, 25.0, 20.5. HRMS (ESI) 
calculated for C19H20INO3 [M]
+ 460.0386, found 437.0369. 
(4-(5-(Benzyloxy)-N-methyl-5-oxopentanamido)phenyl)(4-methoxyphenyl)iodonium 
hexafluorophosphate(V) 
 
In a N2-charged glove box, TEDA-BF4 (179 mg, 0.39 mmol) is dissolved in 1 mL 
acetonitrile. Trimethylsilyl acetate (133 mg, 1.01 mmol) is added dropwise and the 
solution is stirred for 5 minutes. The solution was added to a solution of benzyl 5-((4-
iodophenyl)(methyl)amino)-5-oxopentanoate (170 mg, 0.39 mmol) dissolved in 1 mL 
acetonitrile in a 100 mL Schlenk flask. The flask was removed from the glove box, and 
stirred for 6 hours at 40 °C. The flask was brought back into the glove box, and 
potassium (4-methoxyphenyl) trifluoroborate (83 mg, 0.39 mmol) was added. 
Trimethylsilyl trifluoroacetate (72 mg, 0.39 mmol) was added dropwise, and the solution 
was stirred for 10 minutes in the dark glove box. The flask was brought out of the glove 
N O
O O
I
PF6
MeO
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box, and the solvent was removed in vacuo. The yellow oil was dissolved in 
dichloromethane, washed with DI water (1x), acetate buffer (NaOAc : HOAc = 0.5 M:0.5 
M, pH = 5) (3x) and DI water (2x). Solvent was again removed, and the clear oil was 
dissolved in acetonitrile. Sodium hexafluorophosphate (394 mg, 2.33 mmol) was 
dissolved in minimal DI water and added dropwise. The solution was stirred for 1 hour, 
and then organic solvent was removed in vacuo. The aqueous suspension was extracted 
with dichloromenthane, and the organic fractions were combined. Solvent was removed 
in vacuo. The crude oil was sonicated in pentane and recrystallized from ethyl 
acetate/ether. (155 mg, 58%) 1H NMR (CD3CN, 700 MHz)  8.06 (d, J = 8.6 Hz, 2 H), 
8.05 (d, J = 9.0 Hz, 2 H) 7.41 (d, J = 8.6 Hz, 2 H), 7.38 (m, J = 7.0 Hz, 5 H), 7.09 (d, J = 
9.5 Hz, 2 H), 5.05 (s, 2 H), 3.86 (s, 3 H), 3.22 (s, 3 H), 2.35 (m, J = 7.7 Hz, 2 H), 2.27 (s, 
2 H), 1.84 (m, J = 7.4 Hz, 2 H) 13C NMR (CDCl3, 276 MHz)  173.9, 164.5, 149.3, 
138.8, 137.6, 131.7, 129.6, 129.1, 129.1, 119.3, 102.5, 66.8, 56.8, 56.8, 37.8, 33.9, 21.3, 
14.6. 19F NMR (CD3CN, 276 MHz, 25C)  -73.0 (d, J = -707.0 Hz, PF6-, 6 F). HRMS 
(ESI) calculated for C19H21INO4
+ [M]+ 544.0985, found 544.0992 
 
benzyl 4-(4-iodophenoxy)butanoate 
 
4-(4-iodophenoxy)butanoic acid (1.0 g, 3.268 mmol), triphenyl phosphine (1.559 g, 
5.94216 mmol), and benzyl alcohol (0.321 g, 2.971 mmol) were dissolved in 30 mL 
tetrahydrofuran, and cooled to 0°C. Diisopropylazodicarboxylate (0.600 g, 2.971 mmol) 
was added dropwise, and the solution was stirred for 18 hours at room temperature. 
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Solvent was removed and the residue was dissolved in diethyl ether, washed with DI 
water, and the organic layers were collected. Solvent was removed in vacuo and purified 
by flash chromatography (100% hexanes). 1.24 g (quantitative yield. 1HNMR (CD3CN, 
400 MHz, 25°C) δ 7.56 (d , J = 8.7, 2 H), δ 7.33 (m, J = 1.5, 5 H), δ 6.69 (d, J = 8.7, 2 
H), δ 5.10 (s, 3 H), δ 3.96 (t , J = 6.3, 2 H) δ 2.50 (t, J = 7.3, 2 H) δ 2.18 (s, 2 H), δ 2.03 
(m, J = 6.76, 2 H)  13C NMR (CD3CN, 276 MHz) 25.3, 31.3, 66.9, 67.9, 83.1, 118.1, 
129.1, 129.1, 129.5, 137.6, 139.2, 159.9, 173.7 HRMS (ESI) calculated for C17H17IO3
 
[M]+ 419.0120, found 419.0112 
 
 
benzyl 4-(4-((4-methoxyphenyl)(((trifluoromethyl)sulfonyl)oxy)-ë3-
iodanyl)phenoxy)butanoate 
 
Under a N2-charged glove box atmosphere, trimethylsilyl acetate (0.270 mg, 2.04183 
mmol) was dissolved in 2 mL acetonitrile, and added dropwise to a stirring solution of F-
TEDA-BF4 (0.361 g, 1.02091 mmol) in acetonitrile. The solution was then added to 
benzyl 4-(4-iodophenoxy)butanoate (0.300 g, 0.785 mmol) was dissolved in 3 mL 
acetonitrile, and stirred at room temperature for 4 hours in the absence of light. Potassium 
(4-methoxyphenyl) trifluoroborate (0.168 g, 0.78532 mmol) was added, followed by a 
dropwise addition of a solution of Trimethylsilyl trifluoroacetate (0.132 g, 0.78532 
mmol) dissolved in 1 mL acetonitrile. The solution was stirred for one hour and then 
removed from the N2 atmosphere. The solvent was removed in vacuo, and the residual oil 
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was dissolved in ethyl acetate and washed with DI water. The organic solvent was 
removed in vacuo, and dissolved in minimal acetonitrile. Sodium hexafluorophosphate 
(0.791 g, 4.71192 mmol) was dissolved in minimal DI water and added dropwise. The 
solution was stirred for one hour. The organic solvent was removed in vacuo, and the 
aqueous suspension was extracted with ethyl acetate. The organic layers were combined, 
washed with DI water, dried with sodium sulfate, and evaporated in vacuo. The 
remaining oil was recrystallized from ethyl acetate/MTBE. (0.486 g, 62%)1HNMR 
(CD3CN, 400 MHz, 25°C) δ 7.98 (d, J = 10.8, 2 H), δ 7.96 (d, J = 10.8, 2 H), δ7.33 (m, J 
= 3.0, 5 H), δ 7.03 (d, J = 3.06, 2 H), δ 6.70 (d, J = 4.58, 2H), δ 5.08 (s, 3 H), δ 4.03 (t, J 
= 6.2, 2 H), δ 3.81 (s, 3 H), δ 2.50 (t, J = 7.2, 2 H), δ 2.31 (s, 2 H), δ 2.04 (m, J = 6.7, 2 
H) 19F NMR (CD3CN, 276 MHz, 25C)  -73.0 (d, J = -707.0 Hz, PF6-, 6 F) HRMS (ESI) 
calculated for C24H24IO4
+ [M]+ 503.0695, found 503.0702 
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1H NMR Spectrum of tert-butyl 5-((hexafluoro-λ7-phosphanyl)(4-methoxyphenyl)-λ3-
iodanyl)-1H-indole-1-carboxylate 
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13C NMR Spectrum of tert-butyl 5-((hexafluoro-λ7-phosphanyl)(4-methoxyphenyl)-λ3-
iodanyl)-1H-indole-1-carboxylate 
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19F NMR Spectrum of tert-butyl 5-((hexafluoro-λ7-phosphanyl)(4-methoxyphenyl)-λ3-
iodanyl)-1H-indole-1-carboxylate 
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1H NMR Spectrum of tert-butyl 5-bromo-3-(2-((tert-butoxycarbonyl)amino)ethyl)-1H-
indole-1-carboxylate 
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13C NMR Spectrum of tert-butyl 5-bromo-3-(2-((tert-butoxycarbonyl)amino)ethyl)-1H-
indole-1-carboxylate 
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1H NMR Spectrum of tert-butyl 3-(2-((tert-butoxycarbonyl)amino)ethyl)-5-((hexafluoro-
λ7-phosphanyl)(4-methoxyphenyl)-λ3-iodanyl)-1H-indole-1-carboxylate 
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13C NMR Spectrum of tert-butyl 3-(2-((tert-butoxycarbonyl)amino)ethyl)-5-((hexafluoro-
λ7-phosphanyl)(4-methoxyphenyl)-λ3-iodanyl)-1H-indole-1-carboxylate 
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19F NMR Spectrum of tert-butyl 3-(2-((tert-butoxycarbonyl)amino)ethyl)-5-((hexafluoro-
λ7-phosphanyl)(4-methoxyphenyl)-λ3-iodanyl)-1H-indole-1-carboxylate 
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1H NMR Spectrum of 1-(3-iodo-1H-indol-1-yl)ethan-1-one 
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13C NMR Spectrum of 1-(3-iodo-1H-indol-1-yl)ethan-1-one 
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1H NMR Spectrum of (1-acetyl-1H-indol-3-yl)(4-methoxyphenyl)-l3-iodanyl 
trifluoromethanesulfonate 
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13C NMR Spectrum of (1-acetyl-1H-indol-3-yl)(4-methoxyphenyl)-l3-iodanyl 
trifluoromethanesulfonate 
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19F NMR Spectrum of (1-acetyl-1H-indol-3-yl)(4-methoxyphenyl)-l3-iodanyl 
trifluoromethanesulfonate 
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1H NMR Spectrum of (4-methoxyphenyl)(1-tosyl-1H-indol-3-yl)-λ3-iodanyl 
trifluoromethanesulfonate 
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13C NMR Spectrum of (4-methoxyphenyl)(1-tosyl-1H-indol-3-yl)-λ3-iodanyl 
trifluoromethanesulfonate 
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19F NMR Spectrum of (4-methoxyphenyl)(1-tosyl-1H-indol-3-yl)-λ3-iodanyl 
trifluoromethanesulfonat
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1H NMR Spectrum of (5-bromo-1-tosyl-1H-indol-3-yl)(4-methoxyphenyl)-λ3-iodanyl 
trifluoromethanesulfonate 
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13C NMR Spectrum of (5-bromo-1-tosyl-1H-indol-3-yl)(4-methoxyphenyl)-λ3-iodanyl 
trifluoromethanesulfonate 
 
  
  
88 
19F NMR Spectrum of (5-bromo-1-tosyl-1H-indol-3-yl)(4-methoxyphenyl)-λ3-iodanyl 
trifluoromethanesulfonate 
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1H NMR Spectrum of 5-((4-iodophenyl)(methyl)amino)-5-oxopentanoic acid 
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13C NMR Spectrum of 5-((4-iodophenyl)(methyl)amino)-5-oxopentanoic acid 
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1H NMR Spectrum of benzyl 5-((4-iodophenyl)(methyl)amino)-5-oxopentanoate 
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13C NMR Spectrum of benzyl 5-((4-iodophenyl)(methyl)amino)-5-oxopentanoate 
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1H NMR Spectrum of benzyl 5-((4-((4-methoxyphenyl)(((trifluoromethyl)sulfonyl)oxy)-
λ3-iodanyl)phenyl)(methyl)amino)-5-oxopentanoate 
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13C NMR Spectrum of benzyl 5-((4-((4-methoxyphenyl)(((trifluoromethyl)sulfonyl)oxy)-
λ3-iodanyl)phenyl)(methyl)amino)-5-oxopentanoate 
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19F NMR Spectrum of benzyl 5-((4-((4-methoxyphenyl)(((trifluoromethyl)sulfonyl)oxy)-
λ3-iodanyl)phenyl)(methyl)amino)-5-oxopentanoate 
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1H NMR Spectrum of benzyl 4-(4-iodophenoxy)butanoate 
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13C NMR Spectrum of benzyl 4-(4-iodophenoxy)butanoate 
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1H NMR Spectrum of benzyl 4-(4-((4-methoxyphenyl)(((trifluoromethyl)sulfonyl)oxy)-
l3-iodanyl)phenoxy)butanoate 
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13C NMR Spectrum of benzyl 4-(4-((4-methoxyphenyl)(((trifluoromethyl)sulfonyl)oxy)-
l3-iodanyl)phenoxy)butanoate 
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19F NMR Spectrum of benzyl 4-(4-((4-methoxyphenyl)(((trifluoromethyl)sulfonyl)oxy)-
l3-iodanyl)phenoxy)butanoate
 
I O
O
O
O
O
T
f
  
101 
REFERENCES 
 
(1) Stang, P.J. J. Org. Chem. 2003, 68,   2997-3008    
(2)  Toxicity of Iodine http://www.livestrong.com/article/479473-toxicity-of-iodine/ 
(Accessed November 5, 2015) 
(3) Flora, G; Gupta, D; Tiwari, A Interdiscip Toxicol 2012 5(2):47-48 
(4) Adal, A. Heavy Metal Toxicity http://emedicine.medscape.com/article/814960-
overview (Accessed November 7, 2015). 
(5) Chemicool http://www.chemicool.com/elements/ (Accessed November 7, 2015) 
(6) Zhdankin, V.V. Arkivoc 2009 1-62 
(7) Stang, P.J. Chem. Rev. 1996, 96, 1123-1178 
(8) Ochiai, M; Sumi, K; Takaoka, Y; Kunishima, M; Nagao, Y; Shiro, M; Fujita, E.  
Tetrahedron. 1988, 44(13):4095-4112 
(9) Alcock, N. W.; Countryman, R. M.; Esperas, S.; Sawyer, J. F. J. Chem. Soc., 
Dalton Trans. 1979, 854 
(10) Wang, B; Cerny, R; Uppaluri, S; Kempinger, J; DiMagno, S; J Fluor Chem 2010 
131(11): 1113-1121 
(11) Doub, L. U.S. patent 3,422,152; Chem. Abstr. 1969, 70, 57407n. 
(12) Jezic, C. U.S. Patent 3,622,586; Chem. Abstr. 1972, 76, 59460x.  
(13) Jezic, Z. U.S. Psatent 3,712,920; Chem. Abstr. 1973, 79, 5254b.  
(14) Jezic, Z. U.S. Patent, 3,734,928; Chem. Abstr. 1973, 79, 42151m.  
(15) Jezic, Z. U.S. Patent 3,759,989; Chem. Abstr.1973, 79, 126065z.  
(16) Jezic, Z. U.S. Patent 3,896,- 140; Chem. Abstr. 1976, 84, 4936s. 
(17) Moyle, C. L. U.S. Patent 3,944,498; Chem. Abstr. 1976, 84, 181912b.  
  
102 
(18) Relenyi, A. G.; Koser, G. F.; Walter, R. W., Jr.; Kruper, W. J.; Shankar, R. B.; 
Zelinko, A. P. U.S. Patent 5,106,407; Chem. Abstr. 1992, 117, 247132f.  
(19) Yamada, Y.; Kashima, K.; Okawara, M., Bull. Chem. Soc. Jpn. 1974, 47 (12), 
3179- 3180.  
(20) Ochiai, M. Reactivities, properties and structures. Springer: 2003; Vol. 224, 5  
(21) Ermert, J.; Hocke, C.; Ludwig, T.; Gail, R.; Coenen, H. H., J. Labelled Compd. 
Radiopharm. 2004, 47 (7), 429-441.  
(22) Ross, T. L.; Ermert, J.; Hocke, C.; Coenen, H. H., J. Am. Chem. Soc. 2007, 129 
(25), 8018-8025.  
(23) Lucas, H. J.; Kennedy, E. R.; Wilmot, C. A., J. Am. Chem. Soc. 1936, 58, 157-
160  
(24) Sandin, R. B.; Kulka, M.; McCready, R., J. Am. Chem. Soc. 1937, 59, 2014-2015  
(25) Grushin, V. V.; Tolstaya, T. P.; Lisichkina, I. N., Izv. Akad. Nauk SSSR, Ser. 
Khim. 1983, (9), 2165-2168  
(26) Hamacher K, Coenen HH, Stocklin G. J. Nucl. Med. 1986, 27(2), 235–8 
(27) Berridge, MS; Apana, SM; Hersh, JM. J. Label Compd. Radiopharm 2009, 52 
543–548 
(28) Pike, V. W.; Aigbirhio, F. I.  J. Chem. Soc., Chem. Commun. 1995, 2215 
(29) Guo, H; Xia, C; Liu, G; Wang, D; Qu, G. Henan Shifan Daxue Xuebao, Ziran 
Kexueban 2010, 38(5) 132-134 
(30) Hopkinson, MN; Sahoo, B; Glorius, F. Adv Synth Catal 2014, 356(14), 2794-
2800. 
  
103 
(31) Yang, Y; Han, J; Wu, X; Mao, S; Yu, J; Wang, L; Synlett 2014, 25(10), 1419-
1424 
(32) Eckert, F; Veito, I; Kaljurand, I; Kutt, A; Klamt, A; Diedenhofen, M; J Comput 
Chem 2008, 30(5) 799-810 
(33) Qin, L; Hu, B; Neumann K.D.; Linstad, E.J.; McCauley, K.; Veness, J.; 
Kempinger, J.J.; DiMagno, S. G.; Publication in Progress 
(34) Szabo, KJ. Science of Synthesis 2014 2 345-376 
(35) Kaushik, NK; Kaushik, N; Attri, P; Kumar, N; Kim, CH; Verma, AK; Choi, EH. 
Molecules 2013 18, 6620-6662 
(36) Andreani, A; Rambaldi, M J Heterocyclic Chem 2009 25(5), 1519-1523 
(37) Pullman, B.; Pullman, A.; Les theories electroniques de la Chimie Organique 
1952  
(38) Bandini, M; Org. Biomol. Chem., 2013, 11, 5206 
(39) D. H. R. Barton, J.-P. Finet, C. Giannotti, F. Halley, J. Chem. Soc., Perkin Trans. 1 
1987, 241-249 
(40) Biffinger, J. C.; Woo Kim, H.; DiMagno, S. G., ChemBioChem 2004, 5(5), 622-
627 
(41) Stang, P. J; Tykwinski, R.; Zhdankin, V. J. Heterocyclic Chem.  1992, 29(4) 
815-818 
(42) Qu, W.; Choi, S-R.; Hou, C.; Zhuang, Z.; Oya, S.; Zhang, W.; Kung, M-P.; 
Manchandra, R.; Skovronsky, D. M.; Kung, H. F. Bioorg. Med. Chem. 2008 
18(17) 4823-4827 
(43) Molander, G.A.; Trice, S. L. J.; Kennedy, S. M.; Dreher, S. D.; Tudge, Matthew 
T. J. Am. Chem. Soc. 2012 134(28) 116677-11673 
  
104 
(44) Sigma Aldrich. (Accessed November 8, 2015) 
(45) Sigma Aldrich. (Accessed November 8, 2015) 
(46) Kirchber, S;Froehlich, R; Studer, A Angew Chem Int Ed 2009, 48(23), 4235-
4238. 
(47) Wang, B; Graskemper, JW; Qin, L; DiMagno, SG. Angew Chem Int Ed 2010, 
49(24), 4079-4083 
(48) Mirau, PA; Shafer, RH; James, TL, Biochem 1982, 21(4), 615-620. 
(49) Takeshi, I, Yoshoioka, M, Depression Frontier, 2006, 4(2), 22-27 
(50) Challacombe, DN; Wheeler, EE, Nutrition and Health 1987 5(3-4), 145-152. 
(51) Byerley, WF; Risch, SC, J Clinic Psychopharm 1985, 5(4), 191-206. 
(52) Dubouzet, JG; Matsuda, F; Ishihara, A; Miyagawa, H; Wakasa, Kyo. Plant 
Biotechnol J, 2013 11(9), 1103-1111. 
(53) Coppen, A; Shaw, DM; Malleson, A; Eccleston, E; Gundy, G; Br. J. Psych. 
1965, 111(10) 993-998. 
(54) Coppen, A; Advances in Pharmacology 1968 6, 283-291. 
(55) Sullivan, JL; Coffey, CE; Basuk, B; Cavenar, JO; Maltbie, AA; Zung, WW  Biol. 
Psychiatry 1980, 15(1), 113-120 
(56) Muratore, M. E.; Holloway, C. A.; Pilling, A. W.; Storer, R. I.; Trevitt, G; 
Dixon, D. J. J. Am. Chem. Soc. 2009 131(31) 10796-10797 
(57) Qin, L. Functionalization of Aromatic Organic Molecules through Thermal 
Decomposition of Diaryliodonium Salts, Ph.D. Thesis, University of Nebraska, 
Lincoln, NE, 2012  
  
105 
(58) Organic Chem Portal. http://www.organic-
chemistry.org/protectivegroups/amino.shtm (Accessed November 8, 2015) 
(59)  Rose, DP; Randall, Z. Clin Chim Acta, 1973 47(1), 45-49 
(60)  Schievelbein, H; Loeschenkohl, K; Kuntze, I; Rahlfs, V. Z KLIN CHEM KLIN 
BIO 1972 10(10), 445-449 
(61)  Lemonnier, A; Lemonnier, F; Chevrel, B; Charpentier, C; Caroli, J. REV FR 
ETUD CLIN BIO, 1967, 12(2), 162-169. 
(62) Lin, J; Raoof, DA; Thomas, DG; Greenson, JK; Giordano, TJ; Robinson, GS; 
Beer, DG. Neoplasia, 2004. 6(1), 74–84. 
(63) Yanagida, O.; Kanai, Y.; Chairoungdua, A.; Kim, D. K.; Segawa, H.; Nii, T.; 
Cha, S. H.; Matsuo, H.; Fukushima, J.-i.; Fukasawa, Y.; Tani, Y.; Taketani, Y.; 
Uchino, H.; Kim, J. Y.; Inatomi, J.; Okayasu, I.; Miyamoto, K.-i.; Takeda, E.; 
Goya, T.; Endou, H.; Biochim. Biophys. Acta; 2001, 1514(2), 291-302 
(64) Habermeier, A; Graf, J; Sandhoefer, BF; Boissel, J-P; Roesch, F; Closs, EI; 
Amino Acids 2015, 47(2), 335-344 
(65) Almuhaideb, A; Papathanasiou, N; & Bomanji, J. Annals of Saudi Medicine, 
2015, 31(1), 3–13.  
(66) Gholami, S; Salavati, A; Houshmand, S; Werner, TJ; Alavi, A. J Nucl Cardiol 
2015, 22(3), 468-479 
(67)  Bunevicius, A; Yuan, H; Lin, Weili. Biomed Res-Int, 2013, 634598 
(68) Venegas, J; Winkler, T; Harris, RS. J Aerosol Med Pulm D, 2013, 26(1), 1-8. 
(69) Ohkam, H; Masuda, H; Ishii, Y;Kanai, Y. J Surg Oncol, 2001, 78(4), 256-271. 
  
106 
(70) Zitro, IM; Kamson, DO; Kiousis, S; Juhasz, C; Mittal, S;Cancer 
Biology&Therapy 2013, 14(4), 333-339 
(71) Juhasz, C;Nahleh, Z; Zitron, I; Chugani, DC; Janabi, MZ; Bandyopadhyay, S; 
Ali-Fehmi, R; Mangner, TJ; Chakraborty, PK; Mittal, S; Muzik, O; Nucl. Med. 
Biol. 2012 39(7), 926-932 
(72) Alkonyi Balint; Mittal Sandeep; Zitron Ian; Chugani Diane C; Kupsky William 
J; Muzik Otto; Chugani Harry T; Sood Sandeep; Juhasz Csaba; J. Neuro-onc. 
2012 107(2) 365-372 
(73) Organic Chem Portal, http://www.organic-
chemistry.org/protectivegroups/amino.shtm. (Accessed November 9, 2015.) 
(74) Bycroft, BW; Chhabra, SR; Kellam, B; Smith, P; Tet. Lett., 2003 44(5), 973-976 
(75) Jia, Y; Zhu, J; Synlett 2005 16 2469-2472 
(76) Jones, I. M.; Hamilton, A. D. Org. Lett. 2010, 12(16), 3651-3653 
(77) Jensen, A. E.; Knochel, P.; J Organomet. Chem. 2001, 653(1-2) 122-128 
(78) Li, X.; Yin, W.; Sarma, P. V. V. S.; Zhou, H.; Ma, J.; Cook, J. M. Tet. Lett. 2004, 
45(46) 8569-8573 
(79) Pagoria, P. F.; Mitchell, A. R.; Schmidt, R. D. J. Org. Chem. 1996 61(9) 2934-
2935 
(80) Michaux, J; Retailleau, P; Campagne, J-M; Synlett 2008 10, 1532-1536 
(81) Lupi, V; Penso, M; Foschi, F; Gassa, F; Mihali, V; Tagliabue, A. Chem Comm 
2009, 33, 5012-5014 
(82) Golebiowski, A; Whitehouse, D; Beckett, RP; Van Zandt, M; Ji, MK; Ryder, 
TR; Jagdmann, E; Andreoli, M; Lee, Y; Sheeler, R; Conway, B; Olczak, J; 
  
107 
Mazur, M; Czestkowski, W; Piotrowska, W; Cousido-Siah, A; Ruiz, FX; 
Mitschler, A; Podjarny, A; Schroeter, H. Bioorg Med Chem Lett, 2013, 23(17), 
4837-4841 
(83) Peng, J; Chen, C; Chen, J; Su, X; Xi, C; Chen, H. Org Lett  2014, 16(14), 3776-
3779. 
(84) Kornblum, N; Blackwood, RK. Org Synth, 1957 37, 44-46 
(85) Han, X; Wu, H; Wang, W; Dong, C; Tien, P; Wu, S; Zhou, H-B. Org Biomol 
Chem, 2014 12(41), 8308-8317. 
(86) Torok, B; Sood, A; Bag, S; Kulkarni, A; Borkin, D; Lawler, E; Dasgupta, S; 
Landge, S; Abid, M; Zhou, W; Foster, M; LeVine, H; Toeroek, M. 
ChemMedChem, 2012, 7(5), 910-919. 
(87) Szent-Györgyi, A; Isenber, I; Biochemistry 1960 46 1334-1336 
(88) Mothes, C.; Lavielle, S.; Karoyan, P. J. Org. Chem. 2008 73(17) 6706-6710 
(89) Witulski, B; Buschmann, N; Bergstrasser, U. Tetrahedron, 2000, 56(43), 8473-
8480. 
(90) Ochiai, M; Kitagawa, Y; Takayama, N; Takaoka, Y; Shiro, M. J. Am. Chem. 
Soc. 1999, 121(39), 9233-9234 
(91) Lubriks, D.; Sokolovs, I.; Suna E.; J. Am. Chem. Soc. 2012 134 15436-15442 
(92) Lubriks, D.; Sokolovs, I.; Suna E.; Org. Lett. 2011, 13(16) 4324-4327 
(93) Hu, B.; Miller, W. H.; Neumann, K. D.; Linstad, E. J.; DiMagno, S. G.  Chem—
Eur. J. 2015 21 6394. 
(94) Graskemper, J. Controlling Reductive Elimination From Novel I(III) Salts Using 
a SECURE Method. Master's thesis, University of Nebraska, Lincoln, NE, 2010  
  
108 
(95) Boymond, L.; Rottländer, M.; Gérard, C.; Knochel, P. Angew. Chem. Int. Ed. 
1998 37(12) 1701-1703 
(96) Nakajima, Y; Ozawa, F; Organometallics 2012 31(5), 2009-2015 
(97) Hoffmann, R.W.; Hoelzer, B.; J. Am. Chem. Soc. 2002 124(16), 4204-4205 
(98) Witulski, B; Buschmann, N; Berstrasser, U. Tetrahedron, 2000, 56(43), 8473-
8480 
(99) Karpov, AS. Multicomponent Reactions Based on Sonogashira Coupling. 
Doctoral thesis, Fakultät für Chemie und Geowissenschaften, Institute of 
Organic Chemistry, 2005. 
(100) Kilbourn, MR. Nuclear Science Series. 1990. 
(101) Qu, W; Choi, S-R; Hou, C; Zhuang, Z; Oya, S; Zhang, W; Kung, M-P; 
Manchandra, R; Skovronsky, D. M.; Kung, K. F. Bioorg. Med. Chem. Letter 
2008 18(17) 4823-4827 
(102) Shao, X; Carpenter, GM; Desmond, TJ; Sherman, P; Quesada, CA; Fawaz, M; 
Brooks, AF; Kilbourn, MR; Albin, RL; Frey, KA; Scott, PJH; ACS Med. Chem. 
Lett. 2012 3(11) 936-941 
(103) Namavari, M; Gowrishankar, G; HOehne, A; Jouannot, E; Gambhir, SS; Mol 
Imaging Biol. 2015 17(2) 168-176 
(104) e Vries EFJ; Luurtsema G; Brüssermann M; Elsinga PH: Vaalburg W; Appl 
Radiat Isot. 1999 51 389–394. 
(105) Moon, BS; Kil, HS; Park, JH; Kim, JS; Park, J; Chi, DY; Lee, BC; K, SE Org. 
Biomol. Chem. 2011, 9 8346-8355. 
(106) Ruth, TJ.; Wolf, AP., Radiochim. Acta 1979, 26, 21-24.  
  
109 
(107) Jeon, J;Shen, B; Xiong, L; Miao, Z; Lee, KH; Rao, J; Chin, FT Bioconjugate 
Chem. 2012 23(9) 1902-1908 
(108) Tohma, H.; Maegawa, T.; Kita, Y. Synlett 2003, 723  
(109) Chen, F.-E.; Xie, B.; Zhang, P.; Zhao, J.-F.; Wang, H.; Zhao, L. Synlett 2007, 
619  
(110) Chen, J.-M.; Huang, X. Synthesis 2004, 2459  
(111) Wang, G-P; Chen, Z-C Synthetic Communications 1994 29(16), 2859-2866 
(112) Tohma, H; Takizawa, S; Maegawa, T; Kita, Y Angewandte Chemie, 
International Edition 2000 39(7), 1306-1308 
(113) Ficht, S; Mulbaier, M; Giannis, A Tetrahedron 2001 57(23) 4863-4866 
(114) Chen, D-J; Chen Z-C Synlett 2000 8, 1175-1177 
(115) Marchetto, R; Schreier, S; Nakaie, CR. J Am Chem Soc, 1993, 115(23), 11042-
11043 
(116) Aletras, A; Barlos, K; Gatos, D; Koutsogianni, S;Mamos, P. Int J Pep Prot Res, 
1995, 45(5), 488-496 
(117) Wang, S-S J. Am. Chem. Soc. 1973 95(4) 1328-1333 
(118) Takalo, H; Kankare, J; Hanninen, E  Acta Chem Scan 1988 42(7) 448-454 
(119) Bomanji, J; Levison, DA; Flatman, WD; Horne, T; Bouloux, P.M-G; Ross, G; 
Britton, KE; Besser, GM J Nucl Med 1987 28(6) 973-978 
(120) Wieland, DM; Wu, J; Brown, LE; Mangner, TJ; Swanson, DP; Beierwaltes, 
WH J Nucl Med 1980 21(4) 349-353 
(121) Nakajo, M; Shapiro, B; Copp, J; Kalf, V; Gross, MD; Sisson, JC; Beierwaltes, 
WH J Nucl Med 1983 24(8) 672-682 
  
110 
(122) Home T, Granowska M. Dicks-Mireaux C Br J Radiol 1985 58 476-480. 
(123) Wieland, DM; Brown, LE; Roger, BE, Worthington, KC; Wu, J; Clinthorne, 
NH; Otto, CA; Swanson, DP; Beierwaltes, WH J Nucl Med 1981 22, 22-31 
(124) Shapiro, B; Sisson, JC; Eyre, P; Copp, JE; Dmuchowski, C; Beierwaltes, WH 
Cardiology 1985 72, 137-142 
(125) Shulkin, BL; Shapiro, B. Neuroblastoma: Tumor Biology and Therapy 1990 
171−198  
(126) Hu, B; Vavere, AL; Neumann, KD; Shulkin, BL; DiMagno, SG; Snyder, SE 
ACS ChemChem NeuroSci 2015  
(127) Garg, PK; Garg, S; Zalutsky, MR Nucl Med Biol 1994 21, 97-103 
(128) Koopmans, KP; Brouwers, AH; De Hooge, MN; Van der Horst-Schrivers AN; 
Kema, IP; Wolffenbuttel, BH; De Vries, EG; Jager, PL J Nucl Med 2005 46 
1240-1243 
(129) Zhang, H; Huang, R; Cheung, N-KV; Guo, H; Zanzonico, PB; Thaler, HT; 
Lewis, JS; Blasberg, RG Clin Cancer Res 2014 20, 2182-2191 
(130) Huang, C; Yuan, J; Xu, W; Wang, P Jingxi Huagong Zhongjianti 2008 38(4), 
41- 43  
 
